{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T10:54:08Z","timestamp":1794826448400,"version":"4.9.1"},"reference-count":232,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T00:00:00Z","timestamp":1765497600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T00:00:00Z","timestamp":1765497600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc. Diabetol. \u2013 Endocrinol. Rep."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Chronic hyperglycemia is the defining feature of type 2 diabetes mellitus (T2DM) and a central driver of its long-term complications, including microvascular and macrovascular diseases. Among these, cardiovascular disease (CVD) remains the leading cause of morbidity and mortality in individuals with T2DM. Persistent glucose elevation activates multiple interrelated biochemical pathways, including the polyol pathway, formation of advanced glycation end-products, protein kinase C activation, oxidative stress via several cellular mechanisms, as well as the hexosamine biosynthetic pathway. These processes collectively promote excessive oxidative damage, endothelial dysfunction, inflammation, and adverse cardiac remodeling, ultimately accelerating cardiovascular damage. Research has further revealed that hyperglycemia imprints long-lasting molecular changes through metabolic memory, largely mediated by epigenetic mechanisms such as DNA methylation, histone modifications, and non-coding RNAs, and sustaining vascular dysfunction even after glycemic control. Building on both classical and emerging evidence, this review synthesizes advances in understanding hyperglycemia-induced vascular damage and highlights promising therapeutic targets within these pathways. Strategies under investigation include inhibitors of enzymatic reactive oxygen species sources, modulators of mitochondrial dynamics and function, regulators of protein kinase C, blockers of glycation pathways, and epidrugs targeting epigenetic modifications. By integrating these mechanistic insights with therapeutic innovation, the field is shifting from a narrow focus on glucose lowering to a broader approach aimed at preventing and potentially reversing the vascular complications of diabetes. This perspective emphasizes the urgent need for pathway-specific therapeutic strategies to effectively address the cardiovascular burden of T2DM.<\/jats:p>\n                  <jats:p>\n                    <jats:bold>Graphical Abstract<\/jats:bold>\n                  <\/jats:p>","DOI":"10.1186\/s40842-025-00247-3","type":"journal-article","created":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T23:03:02Z","timestamp":1765494182000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":73,"title":["Chronic hyperglycemia and cardiovascular dysfunction: an in-depth exploration of metabolic and cellular pathways in type 2 diabetes mellitus"],"prefix":"10.1186","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-0266-8489","authenticated-orcid":false,"given":"Araiz","family":"Hussain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,12]]},"reference":[{"issue":"3","key":"247_CR1","first-page":"641","volume":"10","author":"AA Yameny","year":"2024","unstructured":"Yameny AA. Diabetes mellitus overview 2024. J Educ Chang Biosci Appl Res. 2024, Sep, 28;10(3):641\u201345.","journal-title":"J Educ Chang Biosci Appl Res"},{"key":"247_CR2","doi-asserted-by":"publisher","first-page":"3611","DOI":"10.2147\/DMSO.S275898","volume":"13","author":"YT Wondmkun","year":"2020","unstructured":"Wondmkun YT. Obesity, insulin resistance, and type 2 diabetes: associations and therapeutic implications. DMSO. 2020 Oct;13:3611\u201316.","journal-title":"DMSO"},{"key":"247_CR3","first-page":"1 p","volume-title":"IDF diabetes atlas","author":"D Magliano","year":"2021","unstructured":"Magliano D, Boyko EJ. IDF diabetes atlas. 10th edition. Brussels: International Diabetes Federation; 2021. p. 1.","edition":"10th"},{"issue":"1","key":"247_CR4","doi-asserted-by":"publisher","first-page":"17016","DOI":"10.1038\/nrdp.2017.16","volume":"3","author":"A Katsarou","year":"2017","unstructured":"Katsarou A, Gudbj\u00f6rnsdottir S, Rawshani A, Dabelea D, Bonifacio E, Anderson BJ, et al. Type 1 diabetes mellitus. Nat Rev Dis Primers. 2017 Mar 30;3(1):17016.","journal-title":"Nat Rev Dis Primers"},{"issue":"3","key":"247_CR5","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s10741-017-9665-9","volume":"23","author":"A Kaplan","year":"2018","unstructured":"Kaplan A, Abidi E, El-Yazbi A, Eid A, Booz GW, Zouein FA. Direct cardiovascular impact of SGLT2 inhibitors: mechanisms and effects. Heart Fail Rev. 2018 May;23(3):419\u201337.","journal-title":"Heart Fail Rev"},{"issue":"11","key":"247_CR6","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.mpmed.2010.08.008","volume":"38","author":"G Smushkin","year":"2010","unstructured":"Smushkin G, Vella A. What is type 2 diabetes? Medicine. 2010 Nov;38(11):597\u2013601.","journal-title":"Medicine"},{"issue":"3","key":"247_CR7","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s10741-018-9703-2","volume":"23","author":"JS Custodio","year":"2018","unstructured":"Custodio JS, Duraes AR, Abreu M, Albuquerque Rocha N, Roever L. SGLT2 inhibition and heart failure-current concepts. Heart Fail Rev. 2018, May;23(3):409\u201318.","journal-title":"Heart Fail Rev"},{"issue":"15","key":"247_CR8","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","volume":"383","author":"CP Cannon","year":"2020","unstructured":"Cannon CP, Pratley R, Dagogo-Jack S, Mancuso J, Huyck S, Masiukiewicz U, et al. Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med. 2020 Oct 8;383(15):1425\u201335.","journal-title":"N Engl J Med"},{"key":"247_CR9","volume-title":"Global burden of disease, 2021: findings from the GBD, 2021 study","author":"Institute for Health Metrics and Evaluation","year":"2024","unstructured":"Institute for Health Metrics and Evaluation. Global burden of disease, 2021: findings from the GBD, 2021 study. Seattle, WA: Institute for Health Metrics and Evaluation (IHME); 2024."},{"key":"247_CR10","unstructured":"World Health Organization. Global report on diabetes. [Internet]. World Health Organization. 2016. Available from: https:\/\/iris.who.int\/handle\/10665\/204871."},{"issue":"11","key":"247_CR11","doi-asserted-by":"publisher","first-page":"e442","DOI":"10.1371\/journal.pmed.0030442","volume":"3","author":"CD Mathers","year":"2006","unstructured":"Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. Samet J, editor. PLoS Med. 2006 Nov 28;3(11):e442.","journal-title":"PLoS Med"},{"issue":"10085","key":"247_CR12","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1016\/S0140-6736(17)30058-2","volume":"389","author":"S Chatterjee","year":"2017","unstructured":"Chatterjee S, Khunti K, Davies MJ. Type 2 diabetes. Lancet. 2017 Jun;389(10085):2239\u201351.","journal-title":"Lancet"},{"issue":"2\u20133","key":"247_CR13","first-page":"88","volume":"10","author":"C Sc","year":"2013","unstructured":"Chen S chi, Tseng CH. Dyslipidemia, kidney disease, and cardiovascular disease in diabetic patients. Rev Diabet Stud. 2013;10(2\u20133):88\u2013100.","journal-title":"Rev Diabet Stud"},{"issue":"1","key":"247_CR14","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1111\/joim.12128","volume":"275","author":"J De Jager","year":"2014","unstructured":"De Jager J, Kooy A, Schalkwijk C, Van Der Kolk J, Lehert P, Bets D, et al. Long-term effects of metformin on endothelial function in type 2 diabetes: a randomized controlled trial. J Intern Med. 2014 Jan;275(1):59\u201370.","journal-title":"J Intern Med"},{"issue":"5","key":"247_CR15","doi-asserted-by":"publisher","first-page":"937","DOI":"10.2337\/diabetes.48.5.937","volume":"48","author":"M Laakso","year":"1999","unstructured":"Laakso M. Hyperglycemia and cardiovascular disease in type 2 diabetes. Diabetes. 1999 May 1;48(5):937\u201342.","journal-title":"Diabetes"},{"key":"247_CR16","unstructured":"Global Burden of Disease Collaborative Network. Global burden of disease study 2021 (GBD 2021) results. [Internet]. Seattle, United States: Institute for Health Metrics and Evaluation (IHME), 2022. 2021. Available from: https:\/\/vizhub.healthdata.org\/gbd-results\/."},{"issue":"1","key":"247_CR17","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1002\/ame2.12001","volume":"1","author":"L Yan","year":"2018","unstructured":"Yan L. Redox imbalance stress in diabetes mellitus: role of the polyol pathway. Anim Model Exp Med. 2018 Mar;1(1):7\u201313.","journal-title":"Anim Model Exp Med"},{"issue":"3","key":"247_CR18","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/S1089-8603(02)00106-4","volume":"7","author":"I Noyman","year":"2002","unstructured":"Noyman I, Marikovsky M, Sasson S, Stark AH, Bernath K, Seger R, et al. Hyperglycemia reduces nitric oxide synthase and glycogen synthase activity in endothelial cells. Nitric Oxide. 2002 Nov 1;7(3):187\u201393.","journal-title":"Nitric Oxide"},{"key":"247_CR19","doi-asserted-by":"publisher","first-page":"636267","DOI":"10.3389\/fendo.2021.636267","volume":"12","author":"S Jannapureddy","year":"2021","unstructured":"Jannapureddy S, Sharma M, Yepuri G, Schmidt AM, Ramasamy R. Aldose Reductase: an emerging target for development of interventions for diabetic cardiovascular complications. Front Endocrinol. 2021 Mar 11;12:636267.","journal-title":"Front Endocrinol"},{"issue":"5","key":"247_CR20","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s11883-001-0076-x","volume":"3","author":"WC Duckworth","year":"2001","unstructured":"Duckworth WC. Hyperglycemia and cardiovascular disease. Curr Atheroscler Rep. 2001 Sep;3(5):383\u201391.","journal-title":"Curr Atheroscler Rep"},{"issue":"1","key":"247_CR21","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1530\/JME-19-0080","volume":"63","author":"PB Pal","year":"2019","unstructured":"Pal PB, Sonowal H, Shukla K, Srivastava SK, Ramana KV. Aldose reductase regulates hyperglycemia-induced HUVEC death via SIRT1\/AMPK-\u03b11\/mTOR pathway. J Mol Endocrinol. 2019 Jul;63(1):11\u201325.","journal-title":"J Mol Endocrinol"},{"issue":"1","key":"247_CR22","doi-asserted-by":"publisher","first-page":"72","DOI":"10.3390\/antiox14010072","volume":"14","author":"A Caturano","year":"2025","unstructured":"Caturano A, Rocco M, Tagliaferri G, Piacevole A, Nilo D, Di Lorenzo G, et al. Oxidative stress and cardiovascular complications in type 2 diabetes: from pathophysiology to lifestyle modifications. Antioxidants. 2025 Jan 9;14(1):72.","journal-title":"Antioxidants"},{"issue":"5","key":"247_CR23","doi-asserted-by":"publisher","first-page":"H1089","DOI":"10.1152\/ajpheart.00615.2024","volume":"328","author":"A Panwar","year":"2025","unstructured":"Panwar A, Malik SO, Adib M, Lopaschuk GD. Cardiac energy metabolism in diabetes: emerging therapeutic targets and clinical implications. Am J Physiol Heart Circ Physiol. 2025 May 1;328(5):H1089\u2013112.","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"1","key":"247_CR24","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/s41387-021-00150-7","volume":"11","author":"LJ Daniels","year":"2021","unstructured":"Daniels LJ, Annandale M, Koutsifeli P, Li X, Bussey CT, Van Hout I, et al. Elevated myocardial fructose and sorbitol levels are associated with diastolic dysfunction in diabetic patients, and cardiomyocyte lipid inclusions in vitro. Nutr Diabetes. 2021 Feb 8;11(1):8.","journal-title":"Nutr Diabetes"},{"key":"247_CR25","doi-asserted-by":"publisher","first-page":"695486","DOI":"10.3389\/fphar.2021.695486","volume":"12","author":"M Annandale","year":"2021","unstructured":"Annandale M, Daniels LJ, Li X, Neale JPH, Chau AHL, Ambalawanar HA, et al. Fructose metabolism and cardiac metabolic stress. Front Pharmacol. 2021 Jun 29;12:695486.","journal-title":"Front Pharmacol"},{"issue":"5","key":"247_CR26","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1093\/eurjpc\/zwae288","volume":"32","author":"Y Heianza","year":"2025","unstructured":"Heianza Y, Sun Q, Wang X, Tiwari S, Watrous JD, Rexrode KM, et al. Plasma levels of polyols erythritol, mannitol, and sorbitol and incident coronary heart disease among women. Eur J Prev Cardiol. 2025 Apr 2;32(5):404\u201314.","journal-title":"Eur J Prev Cardiol"},{"key":"247_CR27","doi-asserted-by":"publisher","first-page":"106326","DOI":"10.1016\/j.phrs.2022.106326","volume":"182","author":"SS Garg","year":"2022","unstructured":"Garg SS, Gupta J. Polyol pathway and redox balance in diabetes. Pharmacol Res. 2022 Aug;182:106326.","journal-title":"Pharmacol Res"},{"issue":"7","key":"247_CR28","doi-asserted-by":"publisher","first-page":"3016","DOI":"10.3390\/ijms26073016","volume":"26","author":"AJ Tashkandi","year":"2025","unstructured":"Tashkandi AJ, Gorman A, McGoldrick Mathers E, Carney G, Yacoub A, Setyaningsih WAW, et al. Metabolic and mitochondrial dysregulations in diabetic cardiac complications. IJMS. 2025 Mar 26;26(7):3016.","journal-title":"IJMS"},{"issue":"4","key":"247_CR29","first-page":"188","volume":"58","author":"MN Ahmad","year":"2020","unstructured":"Ahmad MN, Farah AI, Al-Qirim TM. The cardiovascular complications of diabetes: a striking link through protein glycation. Rom J Intern Med. 2020 Dec 1;58(4):188\u201398.","journal-title":"Rom J Intern Med"},{"issue":"4","key":"247_CR30","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1007\/s00726-010-0779-9","volume":"42","author":"CG Schalkwijk","year":"2012","unstructured":"Schalkwijk CG, Miyata T. Early- and advanced non-enzymatic glycation in diabetic vascular complications: the search for therapeutics. Amino Acids. 2012 Apr;42(4):1193\u2013204.","journal-title":"Amino Acids"},{"issue":"7","key":"247_CR31","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.2337\/db11-0085","volume":"60","author":"N Rabbani","year":"2011","unstructured":"Rabbani N, Godfrey L, Xue M, Shaheen F, Geoffrion M, Milne R, et al. Glycation of LDL by methylglyoxal increases arterial atherogenicity. Diabetes. 2011 Jul 1;60(7):1973\u201380.","journal-title":"Diabetes"},{"issue":"4","key":"247_CR32","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1097\/CRD.0b013e318244e57c","volume":"20","author":"A Prasad","year":"2012","unstructured":"Prasad A, Bekker P, Tsimikas S. Advanced glycation end products and diabetic cardiovascular disease. Cardiol Rev. 2012 Jul;20(4):177\u201383.","journal-title":"Cardiol Rev"},{"issue":"1","key":"247_CR33","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s10020-018-0060-3","volume":"24","author":"SL Fishman","year":"2018","unstructured":"Fishman SL, Sonmez H, Basman C, Singh V, Poretsky L. The role of advanced glycation end-products in the development of coronary artery disease in patients with and without diabetes mellitus: a review. Mol Med. 2018 Dec;24(1):59.","journal-title":"Mol Med"},{"issue":"1","key":"247_CR34","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1097\/00004872-200301000-00002","volume":"21","author":"D Aronson","year":"2003","unstructured":"Aronson D. Cross-linking of glycated collagen in the pathogenesis of arterial and myocardial stiffening of aging and diabetes. J Retailing Hypertens. 2003 Jan;21(1):3\u201312.","journal-title":"J Retailing Hypertens"},{"issue":"2","key":"247_CR35","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1161\/01.HYP.0000111829.46090.92","volume":"43","author":"MT Schram","year":"2004","unstructured":"Schram MT, Henry RMA, Van Dijk RAJM, Kostense PJ, Dekker JM, Nijpels G, et al. Increased central artery stiffness in impaired glucose metabolism and type 2 diabetes: the hoorn study. Hypertension. 2004 Feb;43(2):176\u201381.","journal-title":"Hypertension"},{"issue":"15","key":"247_CR36","doi-asserted-by":"publisher","first-page":"3086","DOI":"10.3390\/nu14153086","volume":"14","author":"J Lee","year":"2022","unstructured":"Lee J, Yun JS, Ko SH. Advanced glycation end products and their effect on vascular complications in type 2 diabetes mellitus. Nutrients. 2022 Jul 27;14(15):3086.","journal-title":"Nutrients"},{"issue":"6","key":"247_CR37","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1161\/CIRCULATIONAHA.106.621854","volume":"114","author":"A Goldin","year":"2006","unstructured":"Goldin A, Beckman JA, Schmidt AM, Creager MA. Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation. 2006 Aug 8;114(6):597\u2013605.","journal-title":"Circulation"},{"issue":"3","key":"247_CR38","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/S0006-2952(00)00548-7","volume":"61","author":"G Sobal","year":"2001","unstructured":"Sobal G, Menzel EJ, Sinzinger H. Calcium antagonists as inhibitors ofin vitro low density lipoprotein oxidation and glycation. Biochemical Pharmacol. 2001 Feb;61(3):373\u201379.","journal-title":"Biochemical Pharmacol"},{"issue":"3","key":"247_CR39","doi-asserted-by":"publisher","first-page":"584","DOI":"10.3390\/cells9030584","volume":"9","author":"AV Poznyak","year":"2020","unstructured":"Poznyak AV, Wu WK, Melnichenko AA, Wetzker R, Sukhorukov V, Markin AM, et al. Signaling pathways and key genes involved in regulation of foam cell formation in atherosclerosis. Cells. 2020 Mar 1;9(3):584.","journal-title":"Cells"},{"issue":"8","key":"247_CR40","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.4239\/wjd.v14.i8.1146","volume":"14","author":"S Bansal","year":"2023","unstructured":"Bansal S, Burman A, Tripathi AK. Advanced glycation end products: key mediator and therapeutic target of cardiovascular complications in diabetes. World J Diabetes. 2023 Aug 15;14(8):1146\u201362.","journal-title":"World J Diabetes"},{"issue":"3","key":"247_CR41","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.ijcard.2011.05.072","volume":"157","author":"S Raposeiras-Roub\u00edn","year":"2012","unstructured":"Raposeiras-Roub\u00edn S, Rodi\u00f1o-Janeiro BK, Grigorian-Shamagian L, Seoane-Blanco A, Moure-Gonz\u00e1lez M, Varela-Rom\u00e1n A, et al. Evidence for a role of advanced glycation end products in atrial fibrillation. Int J Cardiol. 2012 Jun;157(3):397\u2013402.","journal-title":"Int J Cardiol"},{"issue":"12","key":"247_CR42","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1016\/j.ejheart.2007.09.009","volume":"9","author":"JWL Hartog","year":"2007","unstructured":"Hartog JWL, Voors AA, Bakker SJL, Smit AJ, Van Veldhuisen DJ. Advanced glycation end-products (AGEs) and heart failure: pathophysiology and clinical implications. Eur J Heart Fail. 2007 Dec;9(12):1146\u201355.","journal-title":"Eur J Heart Fail"},{"issue":"9","key":"247_CR43","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.2337\/diacare.22.9.1543","volume":"22","author":"BK Kilhovd","year":"1999","unstructured":"Kilhovd BK, Berg TJ, Birkeland KI, Thorsby P, Hanssen KF. Serum levels of advanced glycation end products are increased in patients with type 2 diabetes and coronary heart disease. Diabetes Care. 1999 Sep 1;22(9):1543\u201348.","journal-title":"Diabetes Care"},{"issue":"12","key":"247_CR44","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1046\/j.0742-3071.2001.00638.x","volume":"18","author":"KJ Way","year":"2001","unstructured":"Way KJ, Katai N, King GL. Protein kinase C and the development of diabetic vascular complications. Diabet Med. 2001 Dec;18(12):945\u201359.","journal-title":"Diabet Med"},{"issue":"1","key":"247_CR45","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s12933-022-01535-3","volume":"21","author":"J Sabbatinelli","year":"2022","unstructured":"Sabbatinelli J, Castiglione S, Macr\u00ec F, Giuliani A, Ramini D, Vinci MC, et al. Circulating levels of AGEs and soluble RAGE isoforms are associated with all-cause mortality and development of cardiovascular complications in type 2 diabetes: a retrospective cohort study. Cardiovasc Diabetol. 2022 Jun 6;21(1):95.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"247_CR46","doi-asserted-by":"publisher","first-page":"119","DOI":"10.2337\/dc14-1435","volume":"38","author":"M Kajikawa","year":"2015","unstructured":"Kajikawa M, Nakashima A, Fujimura N, Maruhashi T, Iwamoto Y, Iwamoto A, et al. Ratio of serum levels of AGEs to soluble form of RAGE is a predictor of endothelial function. Diabetes Care. 2015 Jan 1;38(1):119\u201325.","journal-title":"Diabetes Care"},{"issue":"6","key":"247_CR47","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1007\/s10741-017-9634-3","volume":"22","author":"RM Singh","year":"2017","unstructured":"Singh RM, Cummings E, Pantos C, Singh J. Protein kinase C and cardiac dysfunction: a review. Heart Fail Rev. 2017 Nov;22(6):843\u201359.","journal-title":"Heart Fail Rev"},{"issue":"8","key":"247_CR48","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1161\/CIRCRESAHA.110.217117","volume":"106","author":"P Geraldes","year":"2010","unstructured":"Geraldes P, King GL. Activation of protein kinase C isoforms and its impact on diabetic complications. Circ Res. 2010 Apr 30;106(8):1319\u201331.","journal-title":"Circ Res"},{"issue":"15","key":"247_CR49","doi-asserted-by":"publisher","first-page":"8582","DOI":"10.3390\/ijms23158582","volume":"23","author":"FF Jubaidi","year":"2022","unstructured":"Jubaidi FF, Zainalabidin S, Taib IS, Abdul Hamid Z, Mohamad Anuar NN, Jalil J, et al. The role of PKC-MAPK signalling pathways in the development of hyperglycemia-induced cardiovascular complications. IJMS. 2022 Aug 2;23(15):8582.","journal-title":"IJMS"},{"issue":"5961","key":"247_CR50","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/308693a0","volume":"308","author":"Y Nishizuka","year":"1984","unstructured":"Nishizuka Y. The role of protein kinase C in cell surface signal transduction and tumour promotion. Nature. 1984 Apr 1;308(5961):693\u201398.","journal-title":"Nature"},{"issue":"1","key":"247_CR51","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s001090050187","volume":"76","author":"H Ishii","year":"1997","unstructured":"Ishii H, Koya D, King GL. Protein kinase C activation and its role in the development of vascular complications in diabetes mellitus. J Mol Med. 1997 Dec 2;76(1):21\u201331.","journal-title":"J Mol Med"},{"issue":"1","key":"247_CR52","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1161\/hh0102.102359","volume":"90","author":"JA Beckman","year":"2002","unstructured":"Beckman JA, Goldfine AB, Gordon MB, Garrett LA, Creager MA. Inhibition of protein kinase C\u03b2 prevents impaired endothelium-dependent vasodilation caused by hyperglycemia in humans. Circ Res. 2002 Jan 11;90(1):107\u201311.","journal-title":"Circ Res"},{"issue":"1","key":"247_CR53","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1124\/jpet.106.106666","volume":"319","author":"W Zhou","year":"2006","unstructured":"Zhou W, Wang XL, Lamping KG, Lee HC. Inhibition of protein kinase C\u03b2 protects against diabetes-induced impairment in arachidonic acid dilation of small coronary arteries. J Pharmacol Exp Ther. 2006 Oct;319(1):199\u2013207.","journal-title":"J Pharmacol Exp Ther"},{"issue":"4","key":"247_CR54","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1007\/s13105-020-00769-7","volume":"76","author":"H Wang","year":"2020","unstructured":"Wang H, Xu Y, Xu A, Wang X, Cheng L, Lee S, et al. PKC\u03b2\/NF-\u03baB pathway in diabetic atrial remodeling. J Physiol Biochem. 2020 Nov;76(4):637\u201353.","journal-title":"J Physiol Biochem"},{"key":"247_CR55","doi-asserted-by":"publisher","first-page":"1618343","DOI":"10.3389\/fcvm.2025.1618343","volume":"12","author":"S Kant","year":"2025","unstructured":"Kant S, Feng J. Protein kinase C and endothelial dysfunction in select vascular diseases. Front Cardiovasc Med. 2025 Aug 25;12:1618343.","journal-title":"Front. Cardiovasc. Med"},{"issue":"6","key":"247_CR56","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.2337\/diabetes.54.6.1615","volume":"54","author":"M Brownlee","year":"2005","unstructured":"Brownlee M. The pathobiology of diabetic complications. Diabetes. 2005 Jun 1;54(6):1615\u201325.","journal-title":"Diabetes"},{"issue":"4","key":"247_CR57","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1096\/fj.08-120345","volume":"23","author":"E Harja","year":"2009","unstructured":"Harja E, Chang JS, Lu Y, Leitges M, Zou YS, Schmidt AM, et al. Mice deficient in PKC \u03b2 and apolipoprotein E display decreased atherosclerosis. FASEB J. 2009 Apr;23(4):1081\u201391.","journal-title":"Faseb J"},{"issue":"2","key":"247_CR58","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1093\/cvr\/cvv107","volume":"106","author":"MC Durp\u00e8s","year":"2015","unstructured":"Durp\u00e8s MC, Morin C, Paquin-Veillet J, Beland R, Par\u00e9 M, Guimond MO, et al. PKC-\u03b2 activation inhibits IL-18-binding protein causing endothelial dysfunction and diabetic atherosclerosis. Cardiovasc Res. 2015 May 1;106(2):303\u201313.","journal-title":"Cardiovasc Res"},{"issue":"8","key":"247_CR59","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1161\/ATVBAHA.112.301113","volume":"33","author":"L Kong","year":"2013","unstructured":"Kong L, Shen X, Lin L, Leitges M, Rosario R, Zou YS, et al. PKC\u03b2 promotes vascular inflammation and acceleration of atherosclerosis in diabetic ApoE null mice. ATVB. 2013 Aug;33(8):1779\u201387.","journal-title":"ATVB"},{"issue":"10","key":"247_CR60","doi-asserted-by":"publisher","first-page":"18381","DOI":"10.3390\/ijms151018381","volume":"15","author":"Y Saisho","year":"2014","unstructured":"Saisho Y. Glycemic variability and oxidative stress: a link between diabetes and cardiovascular disease? IJMS. 2014 Oct 13;15(10):18381\u2013406.","journal-title":"IJMS"},{"issue":"32","key":"247_CR61","doi-asserted-by":"publisher","first-page":"5695","DOI":"10.2174\/1381612811319320005","volume":"19","author":"T Fiorentino","year":"2013","unstructured":"Fiorentino T, Prioletta A, Zuo P, Folli F. Hyperglycemia-induced oxidative stress and its role in diabetes mellitus related cardiovascular diseases. CPD. 2013 Aug 1;19(32):5695\u2013703.","journal-title":"CPD"},{"issue":"10","key":"247_CR62","doi-asserted-by":"publisher","first-page":"25234","DOI":"10.3390\/ijms161025234","volume":"16","author":"Y Kayama","year":"2015","unstructured":"Kayama Y, Raaz U, Jagger A, Adam M, Schellinger I, Sakamoto M, et al. Diabetic cardiovascular disease induced by oxidative stress. IJMS. 2015 Oct 23;16(10):25234\u201363.","journal-title":"IJMS"},{"key":"247_CR63","doi-asserted-by":"crossref","unstructured":"Xu T, Ding W, Ji X, Ao X, Liu Y, Yu W, et al. Oxidative stress in cell death and cardiovascular diseases. Oxidative Med Cell Longev. 2019 Nov 4;2019:1\u201311.","DOI":"10.1155\/2019\/9030563"},{"issue":"2","key":"247_CR64","doi-asserted-by":"publisher","first-page":"22","DOI":"10.3390\/jcm6020022","volume":"6","author":"K Cervantes Gracia","year":"2017","unstructured":"Cervantes Gracia K, Llanas-Cornejo D, Husi H. CVD and oxidative stress. JCM. 2017 Feb 20;6(2):22.","journal-title":"JCM"},{"issue":"26","key":"247_CR65","first-page":"163","volume":"1","author":"D Bonnefont-Rousselot","year":"2000","unstructured":"Bonnefont-Rousselot D, Bastard JP, Jaudon M, Delattre JY. Consequences of the diabetic status on the oxidant\/antioxidant balance. Diabetes Metab. 2000 Jun;1(26):163\u201376.","journal-title":"Diabetes Metab"},{"issue":"6","key":"247_CR66","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1007\/s12192-023-01361-w","volume":"28","author":"F Zhi","year":"2023","unstructured":"Zhi F, Zhang Q, Liu L, Chang X, Xu H. Novel insights into the role of mitochondria in diabetic cardiomyopathy: molecular mechanisms and potential treatments. Cell Stress Chaperones. 2023 Nov;28(6):641\u201355.","journal-title":"Cell Stress Chaperones"},{"issue":"1","key":"247_CR67","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/s41392-023-01547-9","volume":"8","author":"W Chen","year":"2023","unstructured":"Chen W, Zhao H, Li Y. Mitochondrial dynamics in health and disease: mechanisms and potential targets. Sig Transduct Target Ther. 2023 Sep 6;8(1):333.","journal-title":"Sig Transduct Target Ther"},{"issue":"2","key":"247_CR68","doi-asserted-by":"publisher","first-page":"e12491","DOI":"10.1111\/jpi.12491","volume":"65","author":"M Ding","year":"2018","unstructured":"Ding M, Feng N, Tang D, Feng J, Li Z, Jia M, et al. Melatonin prevents D rp1-mediated mitochondrial fission in diabetic hearts through SIRT 1- PGC 1\u03b1 pathway. J Pineal Res. 2018 Sep;65(2):e12491.","journal-title":"J Pineal Res"},{"issue":"13","key":"247_CR69","doi-asserted-by":"publisher","first-page":"3687","DOI":"10.7150\/thno.33684","volume":"9","author":"L Hu","year":"2019","unstructured":"Hu L, Ding M, Tang D, Gao E, Li C, Wang K, et al. Targeting mitochondrial dynamics by regulating Mfn2 for therapeutic intervention in diabetic cardiomyopathy. Theranostics. 2019;9(13):3687\u2013706.","journal-title":"Theranostics"},{"issue":"1","key":"247_CR70","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s12933-025-02625-8","volume":"24","author":"W Niu","year":"2025","unstructured":"Niu W, Liu X, Deng B, Hong T, Wang C, Yan Y, et al. Piezo1 deletion mitigates diabetic cardiomyopathy by maintaining mitochondrial dynamics via ERK\/Drp1 pathway. Cardiovasc Diabetol. 2025 Mar 20;24(1):127.","journal-title":"Cardiovasc Diabetol"},{"issue":"19","key":"247_CR71","doi-asserted-by":"publisher","first-page":"e024478","DOI":"10.1161\/JAHA.121.024478","volume":"11","author":"J Li","year":"2022","unstructured":"Li J, Qi X, Ramos KS, Lanters E, Keijer J, De Groot N, et al. Disruption of sarcoplasmic reticulum-mitochondrial contacts underlies contractile dysfunction in experimental and human atrial fibrillation: a key role of mitofusin 2. JAHA. 2022 Oct 4;11(19):e024478.","journal-title":"JAHA"},{"issue":"23","key":"247_CR72","doi-asserted-by":"publisher","first-page":"14725","DOI":"10.3390\/ijms232314725","volume":"23","author":"L Qin","year":"2022","unstructured":"Qin L, Xi S. The role of mitochondrial fission proteins in mitochondrial dynamics in kidney disease. IJMS. 2022 Nov 25;23(23):14725.","journal-title":"IJMS"},{"issue":"1","key":"247_CR73","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1161\/CIRCRESAHA.117.311307","volume":"122","author":"K Tsushima","year":"2018","unstructured":"Tsushima K, Bugger H, Wende AR, Soto J, Jenson GA, Tor AR, et al. Mitochondrial reactive oxygen species in lipotoxic hearts induce post-translational modifications of AKAP121, DRP1, and OPA1 that promote mitochondrial fission. Circ Res. 2018 Jan 5;122(1):58\u201373.","journal-title":"Circ Res"},{"issue":"2","key":"247_CR74","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1038\/s41419-021-03502-4","volume":"12","author":"QR Wu","year":"2021","unstructured":"Wu QR, Zheng DL, Liu PM, Yang H, Li LA, Kuang SJ, et al. High glucose induces Drp1-mediated mitochondrial fission via the Orai1 calcium channel to participate in diabetic cardiomyocyte hypertrophy. Cell Death Dis. 2021 Feb 26;12(2):216.","journal-title":"Cell Death Dis"},{"key":"247_CR75","doi-asserted-by":"publisher","first-page":"841523","DOI":"10.3389\/fcell.2022.841523","volume":"10","author":"J Yang","year":"2022","unstructured":"Yang J, Guo Q, Feng X, Liu Y, Zhou Y. Mitochondrial dysfunction in cardiovascular diseases: potential targets for treatment. Front Cell Dev Biol. 2022 May 13;10:841523.","journal-title":"Front. Cell Dev. Biol"},{"issue":"9","key":"247_CR76","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1161\/CIRCULATIONAHA.123.065603","volume":"149","author":"XS Yang","year":"2024","unstructured":"Yang XS, Qiang LS, Zhang T, Ke SW, Xing Y, Xi FW, et al. USP28 serves as a key suppressor of mitochondrial morphofunctional defects and cardiac dysfunction in the diabetic heart. Circulation. 2024 Feb 27;149(9):684\u2013706.","journal-title":"Circulation"},{"key":"247_CR77","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.freeradbiomed.2016.04.001","volume":"100","author":"MD Brand","year":"2016","unstructured":"Brand MD. Mitochondrial generation of superoxide and hydrogen peroxide as the source of mitochondrial redox signaling. Free Radical Biol Med. 2016 Nov;100:14\u201331.","journal-title":"Free Radical Biol Med"},{"issue":"1","key":"247_CR78","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3390\/antiox7010013","volume":"7","author":"J Je\u017eek","year":"2018","unstructured":"Je\u017eek J, Cooper K, Strich R. Reactive oxygen species and mitochondrial dynamics: the Yin and Yang of mitochondrial dysfunction and cancer progression. Antioxidants. 2018 Jan 16;7(1):13.","journal-title":"Antioxidants"},{"issue":"6865","key":"247_CR79","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1038\/414813a","volume":"414","author":"M Brownlee","year":"2001","unstructured":"Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001 Dec 13;414(6865):813\u201320.","journal-title":"Nature"},{"issue":"5","key":"247_CR80","doi-asserted-by":"publisher","first-page":"330","DOI":"10.3109\/15376516.2012.666648","volume":"22","author":"V Selvaraju","year":"2012","unstructured":"Selvaraju V, Joshi M, Suresh S, Sanchez JA, Maulik N, Maulik G. Diabetes, oxidative stress, molecular mechanism, and cardiovascular disease - an overview. Toxicol Mechanisms Methods. 2012 Jun;22(5):330\u201335.","journal-title":"Toxicol Mechanisms Methods"},{"issue":"4","key":"247_CR81","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1161\/01.RES.85.4.357","volume":"85","author":"T Ide","year":"1999","unstructured":"Ide T, Tsutsui H, Kinugawa S, Utsumi H, Kang D, Hattori N, et al. Mitochondrial electron transport complex I is a potential source of oxygen free radicals in the failing myocardium. Circ Res. 1999 Aug 20;85(4):357\u201363.","journal-title":"Circ Res"},{"issue":"6","key":"247_CR82","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nrd3403","volume":"10","author":"GR Drummond","year":"2011","unstructured":"Drummond GR, Selemidis S, Griendling KK, Sobey CG. Combating oxidative stress in vascular disease: NADPH oxidases as therapeutic targets. Nat Rev Drug Discov. 2011 Jun;10(6):453\u201371.","journal-title":"Nat Rev Drug Discov"},{"issue":"5","key":"247_CR83","doi-asserted-by":"publisher","first-page":"727","DOI":"10.3390\/antiox10050727","volume":"10","author":"C Iacobini","year":"2021","unstructured":"Iacobini C, Vitale M, Pesce C, Pugliese G, Menini S. Diabetic complications and oxidative stress: a 20-year voyage back in time and back to the future. Antioxidants. 2021 May 5;10(5):727.","journal-title":"Antioxidants"},{"issue":"2","key":"247_CR84","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.yjmcc.2006.11.011","volume":"42","author":"M Isabelle","year":"2007","unstructured":"Isabelle M, Vergeade A, Moritz F, Dautr\u00e9aux B, Henry JP, Lallemand F, et al. NADPH oxidase inhibition prevents cocaine-induced up-regulation of xanthine oxidoreductase and cardiac dysfunction. J Mol Cell Cardiol. 2007 Feb;42(2):326\u201332.","journal-title":"J Mol and Cellular Cardiol"},{"issue":"1","key":"247_CR85","doi-asserted-by":"publisher","first-page":"3527579","DOI":"10.1155\/2016\/3527579","volume":"2016","author":"MG Battelli","year":"2016","unstructured":"Battelli MG, Polito L, Bortolotti M, Bolognesi A. Xanthine oxidoreductase-derived reactive species: physiological and pathological effects. Reed, TT, editor. Oxidative Med Cell Longev. 2016 Jan;2016(1):3527579.","journal-title":"Oxidative Med Cell Longev"},{"issue":"1","key":"247_CR86","doi-asserted-by":"publisher","first-page":"3768","DOI":"10.1038\/s41598-021-83234-9","volume":"11","author":"T Okuyama","year":"2021","unstructured":"Okuyama T, Shirakawa J, Nakamura T, Murase T, Miyashita D, Inoue R, et al. Association of the plasma xanthine oxidoreductase activity with the metabolic parameters and vascular complications in patients with type 2 diabetes. Sci Rep. 2021 Feb 12;11(1):3768.","journal-title":"Sci Rep"},{"issue":"1","key":"247_CR87","doi-asserted-by":"publisher","first-page":"20816","DOI":"10.1038\/s41598-022-25413-w","volume":"12","author":"M Hasan","year":"2022","unstructured":"Hasan M, Fariha KA, Barman Z, Mou AD, Miah R, Habib A, et al. Assessment of the relationship between serum xanthine oxidase levels and type 2 diabetes: a cross-sectional study. Sci Rep. 2022 Dec 2;12(1):20816.","journal-title":"Sci Rep"},{"issue":"1","key":"247_CR88","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00380-018-1207-4","volume":"34","author":"K Watanabe","year":"2019","unstructured":"Watanabe K, Shishido T, Otaki Y, Watanabe T, Sugai T, Toshima T, et al. Increased plasma xanthine oxidoreductase activity deteriorates coronary artery spasm. Heart Vessels. 2019 Jan;34(1):1\u20138.","journal-title":"Heart Vessels"},{"issue":"6","key":"247_CR89","doi-asserted-by":"publisher","first-page":"H1861","DOI":"10.1152\/ajpheart.1999.276.6.H1861","volume":"276","author":"P Ferdinandy","year":"1999","unstructured":"Ferdinandy P, Panas D, Schulz R. Peroxynitrite contributes to spontaneous loss of cardiac efficiency in isolated working rat hearts. Am J Physiol Heart Circ Physiol. 1999 Jun 1;276(6):H1861\u20137.","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"1","key":"247_CR90","doi-asserted-by":"publisher","first-page":"3383","DOI":"10.1038\/s41467-023-39159-0","volume":"14","author":"X Zhang","year":"2023","unstructured":"Zhang X, Hu C, Ma ZG, Hu M, Yuan XP, Yuan YP, et al. Tisp40 prevents cardiac ischemia\/reperfusion injury through the hexosamine biosynthetic pathway in male mice. Nat Commun. 2023 Jun 8;14(1):3383.","journal-title":"Nat Commun"},{"issue":"2","key":"247_CR91","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1152\/physrev.00043.2019","volume":"101","author":"JC Chatham","year":"2021","unstructured":"Chatham JC, Zhang J, Wende AR. Role of O -linked N -acetylglucosamine protein modification in cellular (patho)physiology. Physiol Rev. 2021 Apr 1;101(2):427\u201393.","journal-title":"Physiol Rev"},{"issue":"10","key":"247_CR92","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1161\/ATVBAHA.119.312192","volume":"39","author":"Y Chen","year":"2019","unstructured":"Chen Y, Zhao X, Wu H. Metabolic stress and cardiovascular disease in diabetes mellitus: the role of protein O -GlcNAc modification. ATVB. 2019 Oct;39(10):1911\u201324.","journal-title":"ATVB"},{"issue":"2","key":"247_CR93","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/gm424","volume":"5","author":"KA Liddy","year":"2013","unstructured":"Liddy KA, White MY, Cordwell SJ. Functional decorations: post-translational modifications and heart disease delineated by targeted proteomics. Genome Med. 2013 Dec;5(2):20.","journal-title":"Genome Med"},{"issue":"7","key":"247_CR94","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/nrm.2017.22","volume":"18","author":"X Yang","year":"2017","unstructured":"Yang X, Qian K. Protein O-GlcNAcylation: emerging mechanisms and functions. Nat Rev Mol Cell Biol. 2017 Jul;18(7):452\u201365.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"2","key":"247_CR95","doi-asserted-by":"publisher","first-page":"H153","DOI":"10.1152\/ajpheart.00206.2015","volume":"310","author":"RF Mapanga","year":"2016","unstructured":"Mapanga RF, Essop MF. Damaging effects of hyperglycemia on cardiovascular function: spotlight on glucose metabolic pathways. Am J Physiol Heart Circ Physiol. 2016 Jan 15;310(2):H153\u201373.","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"1","key":"247_CR96","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.1152\/ajpendo.00329.2005","volume":"290","author":"MG Buse","year":"2006","unstructured":"Buse MG. Hexosamines, insulin resistance, and the complications of diabetes: current status. Am J Physiol Endoc Metab. 2006 Jan;290(1):E1\u20138.","journal-title":"Am J Physiol Endoc Metab"},{"issue":"1","key":"247_CR97","doi-asserted-by":"publisher","first-page":"C139","DOI":"10.1152\/ajpcell.00020.2010","volume":"299","author":"U Rajamani","year":"2010","unstructured":"Rajamani U, Essop MF. Hyperglycemia-mediated activation of the hexosamine biosynthetic pathway results in myocardial apoptosis. Am J Physiol Cell Physiol. 2010 Jul;299(1):C139\u201347.","journal-title":"Am J Physiol Cell Physiol"},{"issue":"19","key":"247_CR98","doi-asserted-by":"publisher","first-page":"7278","DOI":"10.3390\/ijms21197278","volume":"21","author":"SZ Prisco","year":"2020","unstructured":"Prisco SZ, Rose L, Potus F, Tian L, Wu D, Hartweck L, et al. Excess protein O-GlcNAcylation links metabolic derangements to right ventricular dysfunction in pulmonary arterial hypertension. IJMS. 2020 Oct 1;21(19):7278.","journal-title":"IJMS"},{"key":"247_CR99","doi-asserted-by":"publisher","first-page":"984342","DOI":"10.3389\/fendo.2022.984342","volume":"13","author":"M Cairns","year":"2022","unstructured":"Cairns M, Joseph D, Essop MF. The dual role of the hexosamine biosynthetic pathway in cardiac physiology and pathophysiology. Front Endocrinol. 2022 Oct 24;13:984342.","journal-title":"Front Endocrinol"},{"issue":"1","key":"247_CR100","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1038\/s41467-020-15640-y","volume":"11","author":"DH Tran","year":"2020","unstructured":"Tran DH, May HI, Li Q, Luo X, Huang J, Zhang G, et al. Chronic activation of hexosamine biosynthesis in the heart triggers pathological cardiac remodeling. Nat Commun. 2020 Apr 14;11(1):1771.","journal-title":"Nat Commun"},{"issue":"1","key":"247_CR101","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1186\/s10020-024-00939-z","volume":"30","author":"G Damiano","year":"2024","unstructured":"Damiano G, Rinaldi R, Raucci A, Molinari C, Sforza A, Pirola S, et al. Epigenetic mechanisms in cardiovascular complications of diabetes: towards future therapies. Mol Med. 2024 Sep 27;30(1):161.","journal-title":"Mol Med"},{"key":"247_CR102","doi-asserted-by":"crossref","unstructured":"The diabetes control and complications trial (Dcct)\/epidemiology of diabetes interventions and complications (EDIC) study research group. Intensive diabetes treatment and cardiovascular outcomes in type 1 diabetes: the DCCT\/EDIC study 30-year follow-up. Diabetes Care. 2016 May 1;39(5):686\u201393.","DOI":"10.2337\/dc15-1990"},{"key":"247_CR103","doi-asserted-by":"crossref","unstructured":"Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008 Oct 9;359(15):1577\u201389.","DOI":"10.1056\/NEJMoa0806470"},{"key":"247_CR104","doi-asserted-by":"crossref","unstructured":"Prattichizzo F, De Candia P, De Nigris V, Nicolucci A, Ceriello A. Legacy effect of intensive glucose control on major adverse cardiovascular outcome: systematic review and meta-analyses of trials according to different scenarios. Metabolism. 2020 Sep;110:154308.","DOI":"10.1016\/j.metabol.2020.154308"},{"issue":"1","key":"247_CR105","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1186\/s12933-025-02800-x","volume":"24","author":"S Kaimala","year":"2025","unstructured":"Kaimala S, Yassin LK, Hamad MIK, Allouh MZ, Sampath P, AlKaabi J, et al. Epigenetic crossroads in metabolic and cardiovascular health: the role of DNA methylation in type 2 diabetes and cardiovascular diseases. Cardiovasc Diabetol. 2025 May 29;24(1):231.","journal-title":"Cardiovasc Diabetol"},{"issue":"3","key":"247_CR106","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1002\/med.21878","volume":"42","author":"S Kaimala","year":"2022","unstructured":"Kaimala S, Kumar CA, Allouh MZ, Ansari SA, Emerald BS. Epigenetic modifications in pancreas development, diabetes, and therapeutics. Med Res Rev. 2022 May;42(3):1343\u201371.","journal-title":"Med Res Rev"},{"issue":"12","key":"247_CR107","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1007\/s11892-015-0677-3","volume":"15","author":"J Pasquier","year":"2015","unstructured":"Pasquier J, Hoarau-V\u00e9chot J, Fakhro K, Rafii A, Abi Khalil C. Epigenetics and cardiovascular disease in diabetes. Curr Diab Rep. 2015 Dec;15(12):108.","journal-title":"Curr Diab Rep"},{"issue":"21","key":"247_CR108","doi-asserted-by":"publisher","first-page":"11652","DOI":"10.3390\/ijms222111652","volume":"22","author":"GA Raciti","year":"2021","unstructured":"Raciti GA, Desiderio A, Longo M, Leone A, Zatterale F, Prevenzano I, et al. DNA methylation and type 2 diabetes: novel biomarkers for risk assessment? IJMS. 2021 Oct, 28;22(21):11652.","journal-title":"IJMS"},{"issue":"12","key":"247_CR109","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.2337\/db18-0290","volume":"68","author":"A Cardona","year":"2019","unstructured":"Cardona A, Day FR, Perry JRB, Loh M, Chu AY, Lehne B, et al. Epigenome-wide association study of incident type 2 diabetes in a British population: EPIC-Norfolk study. Diabetes. 2019 Dec 1;68(12):2315\u201326.","journal-title":"Diabetes"},{"issue":"1","key":"247_CR110","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1186\/s13059-022-02728-5","volume":"23","author":"A De Mendoza","year":"2022","unstructured":"De Mendoza A, Nguyen TV, Ford E, Poppe D, Buckberry S, Pflueger J, et al. Large-scale manipulation of promoter DNA methylation reveals context-specific transcriptional responses and stability. Genome Biol. 2022 Jul 26;23(1):163.","journal-title":"Genome Biol"},{"issue":"7534","key":"247_CR111","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/nature14192","volume":"517","author":"D Sch\u00fcbeler","year":"2015","unstructured":"Sch\u00fcbeler D. Function and information content of DNA methylation. Nature. 2015 Jan 15;517(7534):321\u201326.","journal-title":"Nature"},{"issue":"1","key":"247_CR112","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/s41419-025-07525-z","volume":"16","author":"J Ouyang","year":"2025","unstructured":"Ouyang J, Wu D, Gan Y, Tang Y, Wang H, Huang J. Unraveling the metabolic\u2012epigenetic nexus: a new frontier in cardiovascular disease treatment. Cell Death Dis. 2025 Mar 18;16(1):183.","journal-title":"Cell Death Dis"},{"issue":"11","key":"247_CR113","doi-asserted-by":"publisher","first-page":"398","DOI":"10.31083\/j.fbl2911398","volume":"29","author":"A Al-Awar","year":"2024","unstructured":"Al-Awar A, Hussain S. Interplay of reactive oxygen species (ROS) and epigenetic remodelling in cardiovascular diseases pathogenesis: a contemporary perspective. Front Biosci (Landmark Ed). 2024 Nov 21;29(11):398.","journal-title":"Front Biosci (landmark Ed)"},{"key":"247_CR114","doi-asserted-by":"publisher","first-page":"1108126","DOI":"10.3389\/fendo.2023.1108126","volume":"14","author":"S Hu","year":"2023","unstructured":"Hu S, Chen L, Zeng T, Wang W, Yan Y, Qiu K, et al. DNA methylation profiling reveals novel pathway implicated in cardiovascular diseases of diabetes. Front Endocrinol. 2023 Feb 15;14:1108126.","journal-title":"Front Endocrinol"},{"issue":"1","key":"247_CR115","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1186\/s12920-023-01689-3","volume":"16","author":"Y He","year":"2023","unstructured":"He Y, Chen X, Liu M, Zuo L, Zhai Z, Zhou L, et al. The potential DNA methylation markers of cardiovascular disease in patients with type 2 diabetes. BMC Med Genomics. 2023 Oct 12;16(1):242.","journal-title":"BMC Med Genomics"},{"issue":"1","key":"247_CR116","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s13148-024-01722-x","volume":"16","author":"A Desiderio","year":"2024","unstructured":"Desiderio A, Pastorino M, Campitelli M, Longo M, Miele C, Napoli R, et al. DNA methylation in cardiovascular disease and heart failure: novel prediction models? Clin Epigenet. 2024 Aug 22;16(1):115.","journal-title":"Clin Epigenet"},{"issue":"Supplement_1","key":"247_CR117","doi-asserted-by":"publisher","first-page":"ehae666. 2750","DOI":"10.1093\/eurheartj\/ehae666.2750","volume":"45","author":"S Gibbs","year":"2024","unstructured":"Gibbs S, Jones GT, Earle NJ, Poppe KK, Cameron VA, Fakahau PT, et al. DNA methylation in the TXNIP gene is associated with type 2 diabetes in pacific peoples living in NZ. Eur Heart J. 2024 Oct 28;45(Supplement_1):ehae666.2750.","journal-title":"Eur Heart J"},{"issue":"5","key":"247_CR118","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1111\/j.1464-5491.2007.02109.x","volume":"24","author":"MMJ Van Greevenbroek","year":"2007","unstructured":"Van Greevenbroek MMJ, Vermeulen VMM, Feskens EJM, Evelo CT, Kruijshoop M, Hoebee B, et al. Genetic variation in thioredoxin interacting protein (TXNIP) is associated with hypertriglyceridaemia and blood pressure in diabetes mellitus. Diabet Med. 2007 May;24(5):498\u2013504.","journal-title":"Diabet Med"},{"issue":"4","key":"247_CR119","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.3390\/ijms22041693","volume":"22","author":"A Domingues","year":"2021","unstructured":"Domingues A, Jolibois J, Marquet De Roug\u00e9 P, Nivet-Antoine V. The emerging role of TXNIP in ischemic and cardiovascular diseases; a novel marker and therapeutic target. IJMS. 2021 Feb 8;22(4):1693.","journal-title":"IJMS"},{"issue":"2","key":"247_CR120","doi-asserted-by":"publisher","first-page":"C570","DOI":"10.1152\/ajpcell.00201.2022","volume":"323","author":"Z Chen","year":"2022","unstructured":"Chen Z, Natarajan R. Epigenetic modifications in metabolic memory: what are the memories, and can we erase them? Am J Physiol Cell Physiol. 2022 Aug 1;323(2):C570\u201382.","journal-title":"Am J Physiol-Cell Physiol"},{"issue":"1","key":"247_CR121","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1097\/CCM.0b013e3181b4a854","volume":"38","author":"YH Kao","year":"2010","unstructured":"Kao YH, Chen YC, Cheng CC, Lee TI, Chen YJ, Chen SA. Tumor necrosis factor-\u03b1 decreases sarcoplasmic reticulum Ca2\u00b1ATPase expressions via the promoter methylation in cardiomyocytes*. Crit Care Med. 2010 Jan;38(1):217\u201322.","journal-title":"Crit Care Med"},{"issue":"1\u20133","key":"247_CR122","first-page":"331","volume":"23","author":"H M\u00f6nkemann","year":"2002","unstructured":"M\u00f6nkemann H, De Vriese AS, Blom HJ, Kluijtmans LAJ, Heil SG, Schild HH, et al. Early molecular events in the development of the diabetic cardiomyopathy. Amino Acids. 2002 Sep 1;23(1\u20133):331\u201336.","journal-title":"Amino Acids"},{"issue":"9","key":"247_CR123","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.3390\/ijms18091892","volume":"18","author":"L Hardy","year":"2017","unstructured":"Hardy L, Frisdal E, Le Goff W. Critical role of the human ATP-binding cassette G1 transporter in cardiometabolic diseases. IJMS. 2017 Sep 2;18(9):1892.","journal-title":"IJMS"},{"issue":"8","key":"247_CR124","doi-asserted-by":"publisher","first-page":"e102265","DOI":"10.1371\/journal.pone.0102265","volume":"9","author":"P Peng","year":"2014","unstructured":"Peng P, Wang L, Yang X, Huang X, Ba Y, Chen X, et al. A preliminary study of the relationship between promoter methylation of the ABCG1, GALNT2 and HMGCR genes and coronary heart disease. Coleman WB, editor. PLoS One. 2014 Aug 1;9(8):e102265.","journal-title":"PLoS One"},{"issue":"1","key":"247_CR125","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s13148-023-01533-6","volume":"15","author":"J Jin","year":"2023","unstructured":"Jin J, Zhao X, Zhu C, Li M, Wang J, Fan Y, et al. Hypomethylation of ABCG1 in peripheral blood as a potential marker for the detection of coronary heart disease. Clin Epigenet. 2023 Jul 28;15(1):120.","journal-title":"Clin Epigenet"},{"key":"247_CR126","doi-asserted-by":"publisher","first-page":"113984","DOI":"10.1016\/j.biopha.2022.113984","volume":"156","author":"D Li","year":"2022","unstructured":"Li D, Zhang L, He Y, Zhou T, Cheng X, Huang W, et al. Novel histone post-translational modifications in diabetes and complications of diabetes: the underlying mechanisms and implications. Biomed Pharmacother. 2022 Dec;156:113984.","journal-title":"Biomed Pharmacother"},{"issue":"23","key":"247_CR127","doi-asserted-by":"publisher","first-page":"16985","DOI":"10.3390\/ijms242316985","volume":"24","author":"HS Ibrahim","year":"2023","unstructured":"Ibrahim HS, Sippl W. Histone acetyltransferase and deacetylase inhibitors-new aspects and developments. IJMS. 2023 Nov 30;24(23):16985.","journal-title":"IJMS"},{"issue":"1","key":"247_CR128","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s12964-020-00681-z","volume":"19","author":"S Huang","year":"2021","unstructured":"Huang S, Chen G, Sun J, Chen Y, Wang N, Dong Y, et al. Histone deacetylase 3 inhibition alleviates type 2 diabetes mellitus-induced endothelial dysfunction via NRF2. Cell Commun Signal. 2021 Dec;19(1):35.","journal-title":"Cell Commun Signal"},{"issue":"12","key":"247_CR129","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1093\/cvr\/cvae144","volume":"120","author":"SL Baumgardt","year":"2024","unstructured":"Baumgardt SL, Fang J, Fu X, Liu Y, Xia Z, Zhao M, et al. Genetic deletion or pharmacologic inhibition of histone deacetylase 6 protects the heart against ischaemia\/reperfusion injury by limiting tumour necrosis factor alpha-induced mitochondrial injury in experimental diabetes. Cardiovasc Res. 2024 Oct 14;120(12):1456\u201371.","journal-title":"Cardiovasc Res"},{"issue":"1","key":"247_CR130","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s10020-022-00441-4","volume":"28","author":"MA Carrillo-Sepulveda","year":"2022","unstructured":"Carrillo-Sepulveda MA, Maddie N, Johnson CM, Burke C, Lutz O, Yakoub B, et al. Vascular hyperacetylation is associated with vascular smooth muscle dysfunction in a rat model of non-obese type 2 diabetes. Mol Med. 2022 Dec;28(1):30.","journal-title":"Mol Med"},{"issue":"2","key":"247_CR131","doi-asserted-by":"publisher","first-page":"328","DOI":"10.2337\/dbi20-0030","volume":"70","author":"R Natarajan","year":"2021","unstructured":"Natarajan R. Epigenetic mechanisms in diabetic vascular complications and metabolic memory: the 2020 Edwin Bierman award lecture. Diabetes. 2021 Feb 1;70(2):328\u201337.","journal-title":"Diabetes"},{"issue":"9","key":"247_CR132","doi-asserted-by":"publisher","first-page":"8891","DOI":"10.1007\/s11033-012-1756-z","volume":"39","author":"XY Yu","year":"2012","unstructured":"Yu XY, Geng YJ, Liang JL, Zhang S, Lei HP, Zhong SL, et al. High levels of glucose induce \u201cmetabolic memory\u201d in cardiomyocyte via epigenetic histone H3 lysine 9 methylation. Mol Biol Rep. 2012 Sep;39(9):8891\u201398.","journal-title":"Mol Biol Rep"},{"issue":"1","key":"247_CR133","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s12933-024-02196-0","volume":"23","author":"J S\u00e1nchez-Ceinos","year":"2024","unstructured":"S\u00e1nchez-Ceinos J, Hussain S, Khan AW, Zhang L, Almahmeed W, Pernow J, et al. Repressive H3K27me3 drives hyperglycemia-induced oxidative and inflammatory transcriptional programs in human endothelium. Cardiovasc Diabetol. 2024 Apr 5;23(1):122.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"247_CR134","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s12933-025-02646-3","volume":"24","author":"XB Tuo","year":"2025","unstructured":"Tuo XB, Rong WS, Wu Q, Hang XY, Qiu HY, Huang W, et al. BDH1 overexpression alleviates diabetic cardiomyopathy through inhibiting H3K9bhb-mediated transcriptional activation of LCN2. Cardiovasc Diabetol. 2025 Feb 28;24(1):101.","journal-title":"Cardiovasc Diabetol"},{"issue":"4","key":"247_CR135","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1093\/nar\/gkad1142","volume":"52","author":"C Diener","year":"2024","unstructured":"Diener C, Keller A, Meese E. The miRNA-target interactions: an underestimated intricacy. Nucleic Acids Res. 2024 Feb 28;52(4):1544\u201357.","journal-title":"Nucleic Acids Res"},{"issue":"9","key":"247_CR136","doi-asserted-by":"publisher","first-page":"4589","DOI":"10.3390\/ijms23094589","volume":"23","author":"FR Prandi","year":"2022","unstructured":"Prandi FR, Lecis D, Illuminato F, Milite M, Celotto R, Lerakis S, et al. Epigenetic modifications and non-coding RNA in diabetes-mellitus-induced coronary artery disease: pathophysiological link and new therapeutic frontiers. IJMS. 2022 Apr 21;23(9):4589.","journal-title":"IJMS"},{"issue":"12","key":"247_CR137","doi-asserted-by":"publisher","first-page":"2703","DOI":"10.1007\/s11010-022-04455-8","volume":"477","author":"KL Tong","year":"2022","unstructured":"Tong KL, Tan KE, Lim YY, Tien XY, Wong PF. CircRNA-miRNA interactions in atherogenesis. Mol Cell Biochem. 2022 Dec;477(12):2703\u201333.","journal-title":"Mol Cell Biochem"},{"issue":"1","key":"247_CR138","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1093\/cvr\/cvab013","volume":"118","author":"Y Yao","year":"2022","unstructured":"Yao Y, Song Q, Hu C, Da X, Yu Y, He Z, et al. Endothelial cell metabolic memory causes cardiovascular dysfunction in diabetes. Cardiovasc Res. 2022 Jan 7;118(1):196\u2013211.","journal-title":"Cardiovasc Res"},{"key":"247_CR139","doi-asserted-by":"crossref","unstructured":"Xu CR, Fang QJ. Inhibiting glucose metabolism by miR-34a and miR-125b protects against hyperglycemia-induced cardiomyocyte cell death. Arq Bras Cardiol. 2021 Mar 3;116(3):415\u201322.","DOI":"10.36660\/abc.20190529"},{"issue":"9","key":"247_CR140","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1007\/s00125-022-05733-2","volume":"65","author":"S Vigili De Kreutzenberg","year":"2022","unstructured":"Vigili De Kreutzenberg S, Giannella A, Ceolotto G, Faggin E, Cappellari R, Mazzucato M, et al. A miR-125\/Sirtuin-7 pathway drives the pro-calcific potential of myeloid cells in diabetic vascular disease. Diabetologia. 2022 Sep;65(9):1555\u201368.","journal-title":"Diabetologia"},{"issue":"1","key":"247_CR141","doi-asserted-by":"publisher","first-page":"145","DOI":"10.3390\/diagnostics11010145","volume":"11","author":"N Ismail","year":"2021","unstructured":"Ismail N, Abdullah N, Abdul Murad NA, Jamal R, Sulaiman SA. Long non-coding RNAs (lncRnas) in cardiovascular disease complication of type 2 diabetes. Diagnostics. 2021 Jan 19;11(1):145.","journal-title":"Diagnostics"},{"issue":"9","key":"247_CR142","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.3390\/cells8091015","volume":"8","author":"Y Chi","year":"2019","unstructured":"Chi Y, Wang D, Wang J, Yu W, Yang J. Long non-coding RNA in the pathogenesis of cancers. Cells. 2019 Sep 1;8(9):1015.","journal-title":"Cells"},{"issue":"6","key":"247_CR143","doi-asserted-by":"publisher","first-page":"H1503","DOI":"10.1152\/ajpheart.00607.2024","volume":"327","author":"AD Taylor","year":"2024","unstructured":"Taylor AD, Hathaway QA, Meadows EM, Durr AJ, Kunovac A, Pinti MV, et al. Diabetes mellitus disrupts lncRNA Malat1 regulation of cardiac mitochondrial genome-encoded protein expression. Am J Physiol Heart Circ Physiol. 2024 Dec 1;327(6):H1503\u201318.","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"1","key":"247_CR144","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12902-024-01557-w","volume":"24","author":"J Li","year":"2024","unstructured":"Li J, Wang C, Shao C, Xu J. Expression and diagnostic value of lncRNA MALAT1 and NLRP3 in lower limb atherosclerosis in diabetes. BMC Endocr Disord. 2024 Mar 4;24(1):28.","journal-title":"BMC Endocr Disord"},{"issue":"1","key":"247_CR145","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.18632\/oncotarget.13637","volume":"8","author":"C Zhuo","year":"2017","unstructured":"Zhuo C, Jiang R, Lin X, Shao M. LncRNA H19 inhibits autophagy by epigenetically silencing of DIRAS3 in diabetic cardiomyopathy. Oncotarget. 2017 Jan 3;8(1):1429\u201337.","journal-title":"Oncotarget"},{"issue":"1","key":"247_CR146","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s13062-022-00346-6","volume":"17","author":"T Peng","year":"2022","unstructured":"Peng T, Liu M, Hu L, Guo D, Wang D, Qi B, et al. LncRNA airn alleviates diabetic cardiac fibrosis by inhibiting activation of cardiac fibroblasts via a m6A-IMP2-p53 axis. Biol Direct. 2022 Nov 16;17(1):32.","journal-title":"Biol Direct"},{"issue":"1","key":"247_CR147","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s12933-023-01811-w","volume":"22","author":"K Gopal","year":"2023","unstructured":"Gopal K, Karwi QG, Tabatabaei Dakhili SA, Wagg CS, Zhang L, Sun Q, et al. Aldose reductase inhibition alleviates diabetic cardiomyopathy and is associated with a decrease in myocardial fatty acid oxidation. Cardiovasc Diabetol. 2023 Mar 28;22(1):73.","journal-title":"Cardiovasc Diabetol"},{"issue":"2","key":"247_CR148","doi-asserted-by":"publisher","first-page":"292","DOI":"10.2337\/diab.46.2.292","volume":"46","author":"R Ramasamy","year":"1997","unstructured":"Ramasamy R, Oates PJ, Schaefer S. Aldose reductase inhibition protects diabetic and nondiabetic rat hearts from ischemic injury. Diabetes. 1997 Feb 1;46(2):292\u2013300.","journal-title":"Diabetes"},{"issue":"1","key":"247_CR149","doi-asserted-by":"publisher","first-page":"H75","DOI":"10.1152\/ajpheart.1998.275.1.H75","volume":"275","author":"N Trueblood","year":"1998","unstructured":"Trueblood N, Ramasamy R. Aldose reductase inhibition improves altered glucose metabolism of isolated diabetic rat hearts. Am J Physiol Heart Circ Physiol. 1998 Jul 1;275(1):H75\u201383.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"247_CR150","unstructured":"Wikipedia contributors. Tolrestat. In Wikipedia, the free encyclopedia. 2025. [cited 2025 Aug 18]. Available from: https:\/\/en.wikipedia.org\/w\/index.php?title=Tolrestat&oldid=1289611324."},{"key":"247_CR151","unstructured":"Zhou Y, Zhang YT, Zhao DH, Yu XY, Shen XY, Zhou Y, et al. TTD: therapeutic target database describing target druggability information. In Nucleic Acids Research. 2024 [cited 2025 Aug 19]. Available from: https:\/\/db.idrblab.net\/ttd\/data\/drug\/details\/d06edt#TTDREF00024236."},{"key":"247_CR152","unstructured":"Applied Therapeutics, Inc. Form S-1 registration statement under the securities act of 1933 [Internet]. U.S. Securities and Exchange Commission (SEC); 2020 [cited 2025 Aug 19]. Available from: https:\/\/www.sec.gov\/Archives\/edgar\/data\/1697532\/000104746920000339\/a2240509zs-1.htm."},{"issue":"2","key":"247_CR153","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1111\/jdi.12890","volume":"10","author":"K Sekiguchi","year":"2019","unstructured":"Sekiguchi K, Kohara N, Baba M, Komori T, Naito Y, Imai T, et al. Aldose reductase inhibitor ranirestat significantly improves nerve conduction velocity in diabetic polyneuropathy: a randomized double-blind placebo-controlled study in Japan. J Diabetes Invest. 2019 Mar;10(2):466\u201374.","journal-title":"J Diabetes Invest"},{"issue":"2","key":"247_CR154","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.jacc.2024.03.380","volume":"84","author":"JL Januzzi","year":"2024","unstructured":"Januzzi JL, Butler J, Del Prato S, Ezekowitz JA, Ibrahim NE, Lam CSP, et al. Randomized trial of a selective aldose reductase inhibitor in patients with diabetic cardiomyopathy. J Am Coll Cardiol. 2024 Jul;84(2):137\u201348.","journal-title":"J Am Coll Cardiol"},{"key":"247_CR155","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.ijbiomac.2017.02.104","volume":"99","author":"MM Joglekar","year":"2017","unstructured":"Joglekar MM, Bavkar LN, Sistla S, Arvindekar AU. Effective inhibition of protein glycation by combinatorial usage of limonene and aminoguanidine through differential and synergistic mechanisms. Int J Biol Macromolecules. 2017 Jun;99:563\u201369.","journal-title":"Int J Biol Macromolecules"},{"issue":"4","key":"247_CR156","first-page":"3125","volume":"18","author":"F Magdaleno","year":"2019","unstructured":"Magdaleno F, Christopher BC, Lisette CC, Marlene GA, Omar VA, Guillermina MA, et al. Aminoguanidine reduces diabetes\u2011associated cardiac fibrosis. Exp Ther Med. 2019 Oct 1;18(4):3125\u201338.","journal-title":"Exp Ther Med"},{"issue":"8","key":"247_CR157","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1038\/sj.bjp.0706684","volume":"147","author":"K Chang","year":"2006","unstructured":"Chang K, Hsu K, Tseng C, Lin Y, Cho Y, Tseng Y. Aminoguanidine prevents arterial stiffening and cardiac hypertrophy in streptozotocin-induced diabetes in rats. Br J Pharmacol. 2006 Apr;147(8):944\u201350.","journal-title":"Br J Pharmacol"},{"issue":"1","key":"247_CR158","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1159\/000075627","volume":"24","author":"WK Bolton","year":"2004","unstructured":"Bolton WK, Cattran DC, Williams ME, Adler SG, Appel GB, Cartwright K, et al. Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy. Am J Nephrol. 2004;24(1):32\u201340.","journal-title":"Am J Nephrol"},{"issue":"1","key":"247_CR159","doi-asserted-by":"publisher","first-page":"16010","DOI":"10.1038\/s41598-017-16255-y","volume":"7","author":"D Deluyker","year":"2017","unstructured":"Deluyker D, Ferferieva V, Driesen RB, Verboven M, Lambrichts I, Bito V. Pyridoxamine improves survival and limits cardiac dysfunction after MI. Sci Rep. 2017 Nov 22;7(1):16010.","journal-title":"Sci Rep"},{"issue":"6","key":"247_CR160","doi-asserted-by":"publisher","first-page":"e79","DOI":"10.1111\/1755-5922.12039","volume":"31","author":"F Almeida","year":"2013","unstructured":"Almeida F, Santos-Silva D, Rodrigues T, Matafome P, Cris\u00f3stomo J, Sena C, et al. Pyridoxamine reverts methylglyoxal-induced impairment of survival pathways during heart ischemia. Cardiovasc Ther. 2013 Dec;31(6):e79\u201385.","journal-title":"Cardiovasc Ther"},{"issue":"5","key":"247_CR161","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1111\/dom.14977","volume":"25","author":"MDG Van Den Eynde","year":"2023","unstructured":"Van Den Eynde MDG, Houben AJHM, Scheijen JLJM, Linkens AMA, Niessen PM, Simons N, et al. Pyridoxamine reduces methylglyoxal and markers of glycation and endothelial dysfunction, but does not improve insulin sensitivity or vascular function in abdominally obese individuals: a randomized double-blind placebo-controlled trial. Diabetes Obes Metab. 2023 May;25(5):1280\u201391.","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"247_CR162","doi-asserted-by":"publisher","first-page":"285","DOI":"10.5152\/eurasianjmed.2019.18434","volume":"51","author":"Department of Medical Pharmacology, Eskisehir Osmangazi University, School of Medicine, Eskisehir, Turkey, Toprak C, Yigitaslan, S Department of Medical Pharmacology, Eskisehir Osmangazi University, School of Medicine, Eskisehir, Turkey","year":"2019","unstructured":"Department of Medical Pharmacology, Eskisehir Osmangazi University, School of Medicine, Eskisehir, Turkey, Toprak C, Yigitaslan, S Department of Medical Pharmacology, Eskisehir Osmangazi University, School of Medicine, Eskisehir, Turkey. Alagebrium and complications of diabetes mellitus. Eurasian J Med. 2019 Nov 14;51(3):285\u201392.","journal-title":"Eurasian J Med"},{"issue":"10","key":"247_CR163","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1038\/hr.2014.98","volume":"37","author":"B Zhang","year":"2014","unstructured":"Zhang B, He K, Chen W, Cheng X, Cui H, Zhong W, et al. Alagebrium (ALT-711) improves the anti-hypertensive efficacy of nifedipine in diabetic-hypertensive rats. Hypertens Res. 2014 Oct;37(10):901\u201307.","journal-title":"Hypertens Res"},{"issue":"3","key":"247_CR164","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.cardfail.2004.09.010","volume":"11","author":"WC Little","year":"2005","unstructured":"Little WC, Zile MR, Kitzman DW, Hundley WG, O\u2019Brien TX, DeGroof Rc. The effect of alagebrium chloride (ALT-711), a novel glucose Cross-Link Breaker, in the treatment of elderly patients with diastolic heart failure. J Card Fail. 2005 Apr;11(3):191\u201395.","journal-title":"J Card Fail"},{"issue":"1","key":"247_CR165","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1097\/FJC.0b013e3181ac3a34","volume":"54","author":"D Joshi","year":"2009","unstructured":"Joshi D, Gupta R, Dubey A, Shiwalkar A, Pathak P, Gupta RC, et al. TRC4186, a novel AGE-breaker, improves diabetic cardiomyopathy and nephropathy in ob-ZSF1 model of type 2 diabetes. J Cardiovasc Pharmacol. 2009 Jul;54(1):72\u201381.","journal-title":"J Cardiovasc Pharmacol"},{"key":"247_CR166","doi-asserted-by":"publisher","first-page":"103704","DOI":"10.1016\/j.redox.2025.103704","volume":"84","author":"Z Xiao","year":"2025","unstructured":"Xiao Z, Pan Y, Meng H, Qu Z, Guo L, Kong B, et al. Ubiquitin-specific protease 38 exacerbates diabetic cardiomyopathy via post-translational modification of ACAD11. Redox Biol. 2025 Jul;84:103704.","journal-title":"Redox Biol"},{"issue":"4","key":"247_CR167","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1002\/ddr.21779","volume":"82","author":"R Kumar","year":"2021","unstructured":"Kumar R, Bhargava P, Suchal K, Bhatia J, Arya DS. Targeting AGE-RAGE signaling pathway by Saxagliptin prevents myocardial injury in isoproterenol challenged diabetic rats. Drug Dev Res. 2021 Jun;82(4):589\u201397.","journal-title":"Drug Dev Res"},{"issue":"1","key":"247_CR168","doi-asserted-by":"publisher","first-page":"19632","DOI":"10.1038\/s41598-025-00956-w","volume":"15","author":"L Kong","year":"2025","unstructured":"Kong L, Wang H, Jiang W, Chen Y, Du Z, Zhang Q, et al. Network pharmacology-based study in polymetformin\u2019s new function of blocking ages\/rage pathway curing diabetic complications. Sci Rep. 2025 Jun 4;15(1):19632.","journal-title":"Sci Rep"},{"key":"247_CR169","doi-asserted-by":"crossref","unstructured":"Wang Y, Zhou L, Su W, Huang F, Zhang Y, Yuan XZ, et al. Selective inhibition of PKC \u03b2 2 restores ischemic postconditioning-mediated cardioprotection by modulating autophagy in diabetic rats. J Diabetes Res. 2020 Apr 3;2020:1\u201311.","DOI":"10.1155\/2020\/2408240"},{"issue":"7","key":"247_CR170","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.2337\/db12-1391","volume":"62","author":"S Lei","year":"2013","unstructured":"Lei S, Li H, Xu J, Liu Y, Gao X, Wang J, et al. Hyperglycemia-induced protein kinase C \u03b22 activation induces diastolic cardiac dysfunction in diabetic rats by impairing caveolin-3 expression and Akt\/eNOS signaling. Diabetes. 2013 Jul 1;62(7):2318\u201328.","journal-title":"Diabetes"},{"issue":"2","key":"247_CR171","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1097\/XCS.0000000000001248","volume":"241","author":"JW Nho","year":"2025","unstructured":"Nho JW, Banerjee D, Harris DD, Stone C, Xing H, Kanuparthy M, et al. Protein kinase C-\u03b2 inhibition and survival signaling after simulated cardioplegic-ischemia\/Reperfusion in nondiabetic and diabetic human coronary arterial endothelial cells. J Am Coll Surgeons. 2025 Aug;241(2):118\u201335.","journal-title":"J Am Coll Surgeons"},{"key":"247_CR172","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.xjon.2023.06.014","volume":"15","author":"S Kant","year":"2023","unstructured":"Kant S, Xing H, Liu Y, Harrington EO, Sellke FW, Feng J. Acute protein kinase C beta inhibition preserves coronary endothelial function after cardioplegic hypoxia\/reoxygenation. JTCVS Open. 2023 Sep;15:242\u201351.","journal-title":"JTCVS Open"},{"issue":"4","key":"247_CR173","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1042\/CS20110176","volume":"122","author":"Y Liu","year":"2012","unstructured":"Liu Y, Lei S, Gao X, Mao X, Wang T, Wong GT, et al. PKC\u03b2 inhibition with ruboxistaurin reduces oxidative stress and attenuates left ventricular hypertrophy and dysfuntion in rats with streptozotocin-induced diabetes. Clin Sci. 2012 Feb 1;122(4):161\u201373.","journal-title":"Clin Sci"},{"issue":"4","key":"247_CR174","doi-asserted-by":"publisher","first-page":"H1862","DOI":"10.1152\/ajpheart.01346.2007","volume":"294","author":"L Kong","year":"2008","unstructured":"Kong L, Andrassy M, Chang JS, Huang C, Asai T, Szabolcs MJ, et al. PKC\u03b2 modulates ischemia-reperfusion injury in the heart. Am J Physiol Heart Circ Physiol. 2008 Apr;294(4):H1862\u201370.","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"9","key":"247_CR175","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/s41573-021-00233-1","volume":"20","author":"HJ Forman","year":"2021","unstructured":"Forman HJ, Zhang H. Targeting oxidative stress in disease: promise and limitations of antioxidant therapy. Nat Rev Drug Discov. 2021 Sep;20(9):689\u2013709.","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"247_CR176","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s12933-017-0501-2","volume":"16","author":"M Ding","year":"2017","unstructured":"Ding M, Dong Q, Liu Z, Liu Z, Qu Y, Li X, et al. Inhibition of dynamin-related protein 1 protects against myocardial ischemia-reperfusion injury in diabetic mice. Cardiovasc Diabetol. 2017 Dec;16(1):19.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"247_CR177","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41401-021-00626-3","volume":"43","author":"C Maneechote","year":"2022","unstructured":"Maneechote C, Palee S, Kerdphoo S, Jaiwongkam T, Chattipakorn SC, Chattipakorn N. Modulating mitochondrial dynamics attenuates cardiac ischemia-reperfusion injury in prediabetic rats. Acta Pharmacol Sin. 2022 Jan;43(1):26\u201338.","journal-title":"Acta Pharmacol Sin"},{"key":"247_CR178","doi-asserted-by":"publisher","first-page":"175531","DOI":"10.1016\/j.ejphar.2023.175531","volume":"942","author":"Y Lyu","year":"2023","unstructured":"Lyu Y, Huo J, Jiang W, Yang W, Wang S, Zhang S, et al. Empagliflozin ameliorates cardiac dysfunction in heart failure mice via regulating mitochondrial dynamics. Eur J Pharmacol. 2023 Mar 5;942:175531.","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"247_CR179","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1186\/s12933-018-0790-0","volume":"17","author":"A Durak","year":"2018","unstructured":"Durak A, Olgar Y, Degirmenci S, Akkus E, Tuncay E, Turan B. A SGLT2 inhibitor dapagliflozin suppresses prolonged ventricular-repolarization through augmentation of mitochondrial function in insulin-resistant metabolic syndrome rats. Cardiovasc Diabetol. 2018 Dec;17(1):144.","journal-title":"Cardiovasc Diabetol"},{"key":"247_CR180","doi-asserted-by":"publisher","first-page":"119117","DOI":"10.1016\/j.atherosclerosis.2025.119117","volume":"402","author":"M Sun","year":"2025","unstructured":"Sun M, Lu Z, Chen WM, Lv S, Fu N, Yang Y, et al. N-acetylcysteine therapy reduces major adverse cardiovascular events in patients with type 2 diabetes mellitus. Atherosclerosis. 2025 Mar 1;402:119117.","journal-title":"Atherosclerosis"},{"issue":"5","key":"247_CR181","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1007\/s00125-012-2495-3","volume":"55","author":"K Huynh","year":"2012","unstructured":"Huynh K, Kiriazis H, Du XJ, Love JE, Jandeleit-Dahm KA, Forbes JM, et al. Coenzyme Q10 attenuates diastolic dysfunction, cardiomyocyte hypertrophy and cardiac fibrosis in the db\/db mouse model of type 2 diabetes. Diabetologia. 2012 May;55(5):1544\u201353.","journal-title":"Diabetologia"},{"issue":"4","key":"247_CR182","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s12192-022-01273-1","volume":"27","author":"Y Ji","year":"2022","unstructured":"Ji Y, Leng Y, Lei S, Qiu Z, Ming H, Zhang Y, et al. The mitochondria-targeted antioxidant MitoQ ameliorates myocardial ischemia-reperfusion injury by enhancing PINK1\/Parkin-mediated mitophagy in type 2 diabetic rats. Cell Stress Chaperones. 2022 Jul;27(4):353\u201367.","journal-title":"Cell Stress Chaperones"},{"key":"247_CR183","doi-asserted-by":"publisher","first-page":"823975","DOI":"10.3389\/fphar.2022.823975","volume":"13","author":"H Zheng","year":"2022","unstructured":"Zheng H, Xu N, Zhang Z, Wang F, Xiao J, Ji X. Setanaxib (GKT137831) ameliorates doxorubicin-induced cardiotoxicity by inhibiting the NOX1\/NOX4\/Reactive oxygen species\/MAPK pathway. Front Pharmacol. 2022 Apr 4;13:823975.","journal-title":"Front Pharmacol"},{"issue":"18","key":"247_CR184","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1161\/CIRCULATIONAHA.112.132159","volume":"127","author":"SP Gray","year":"2013","unstructured":"Gray SP, Di Marco E, Okabe J, Szyndralewiez C, Heitz F, Montezano AC, et al. NADPH oxidase 1 plays a key role in diabetes mellitus-accelerated atherosclerosis. Circulation. 2013 May 7;127(18):1888\u2013902.","journal-title":"Circulation"},{"issue":"5","key":"247_CR185","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1007\/s00125-017-4215-5","volume":"60","author":"SP Gray","year":"2017","unstructured":"Gray SP, Jha JC, Kennedy K, Van Bommel E, Chew P, Szyndralewiez C, et al. Combined NOX1\/4 inhibition with GKT137831 in mice provides dose-dependent reno- and atheroprotection even in established micro- and macrovascular disease. Diabetologia. 2017 May;60(5):927\u201337.","journal-title":"Diabetologia"},{"issue":"2","key":"247_CR186","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1111\/jcmm.14870","volume":"24","author":"J Luo","year":"2020","unstructured":"Luo J, Yan D, Li S, Liu S, Zeng F, Cheung CW, et al. Allopurinol reduces oxidative stress and activates NRF2\/p62 to attenuate diabetic cardiomyopathy in rats. J Cellular Mol Med. 2020 Jan;24(2):1760\u201373.","journal-title":"J Cellular Mol Medi"},{"issue":"1","key":"247_CR187","doi-asserted-by":"publisher","first-page":"4554","DOI":"10.1038\/srep04554","volume":"4","author":"J Nomura","year":"2014","unstructured":"Nomura J, Busso N, Ives A, Matsui C, Tsujimoto S, Shirakura T, et al. Xanthine oxidase inhibition by febuxostat attenuates experimental atherosclerosis in mice. Sci Rep. 2014 Apr 1;4(1):4554.","journal-title":"Sci Rep"},{"issue":"2","key":"247_CR188","doi-asserted-by":"publisher","first-page":"100029","DOI":"10.1016\/j.jphyss.2025.100029","volume":"75","author":"T Mitsubayashi","year":"2025","unstructured":"Mitsubayashi T, Suita K, Ohnuki Y, Ishikawa M, Ito A, Matsuo I, et al. Xanthine oxidase inhibitor allopurinol preserves cardiac function after experimental malocclusion induced by occlusal disharmony in mice. J Physiol Sci. 2025 Jul;75(2):100029.","journal-title":"J Physiol Sci"},{"issue":"10","key":"247_CR189","doi-asserted-by":"publisher","first-page":"e008807","DOI":"10.1161\/JAHA.118.008807","volume":"7","author":"Y Yang","year":"2018","unstructured":"Yang Y, Zhao J, Qiu J, Li J, Liang X, Zhang Z, et al. Xanthine oxidase inhibitor allopurinol prevents oxidative stress-mediated atrial remodeling in alloxan-induced diabetes mellitus rabbits. JAHA. 2018 May 15;7(10):e008807.","journal-title":"JAHA"},{"issue":"1","key":"247_CR190","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1038\/s41598-020-80835-8","volume":"11","author":"H Saito","year":"2021","unstructured":"Saito H, Tanaka K, Iwasaki T, Oda A, Watanabe S, Kanno M, et al. Xanthine oxidase inhibitors are associated with reduced risk of cardiovascular disease. Sci Rep. 2021 Jan 14;11(1):1380.","journal-title":"Sci Rep"},{"key":"247_CR191","doi-asserted-by":"crossref","unstructured":"Yang TL, Leu HB, Lin SJ, Horng JL, Shih CM. Cardiovascular outcomes of febuxostat and allopurinol: a long-term Taiwanese nationwide cohort study. J Formos Med Assoc. 2025 Jun; S0929664625002700.","DOI":"10.1016\/j.jfma.2025.05.040"},{"issue":"2","key":"247_CR192","doi-asserted-by":"publisher","first-page":"C331","DOI":"10.1152\/ajpcell.00467.2023","volume":"326","author":"J Hao","year":"2024","unstructured":"Hao J, Zhou J, Hu S, Zhang P, Wu H, Yang J, et al. RTA 408 ameliorates diabetic cardiomyopathy by activating NRF2 to regulate mitochondrial fission and fusion and inhibiting NF-\u03baB-mediated inflammation. Am J Physiol Cell Physiol. 2024 Feb 1;326(2):C331\u201347.","journal-title":"Am J Physiol Cell Physiol"},{"issue":"9","key":"247_CR193","doi-asserted-by":"publisher","first-page":"6319","DOI":"10.1111\/jcmm.14520","volume":"23","author":"J Wang","year":"2019","unstructured":"Wang J, Wang S, Wang W, Chen J, Zhang Z, Zheng Q, et al. Protection against diabetic cardiomyopathy is achieved using a combination of sulforaphane and zinc in type 1 diabetic OVE26 mice. J Cellular Mol Med. 2019 Sep;23(9):6319\u201330.","journal-title":"J Cellular Mol Medi"},{"key":"247_CR194","doi-asserted-by":"publisher","first-page":"154002","DOI":"10.1016\/j.metabol.2019.154002","volume":"102","author":"Y Sun","year":"2020","unstructured":"Sun Y, Zhou S, Guo H, Zhang J, Ma T, Zheng Y, et al. Protective effects of sulforaphane on type 2 diabetes-induced cardiomyopathy via AMPK-mediated activation of lipid metabolic pathways and NRF2 function. Metabolism. 2020 Jan;102:154002.","journal-title":"Metabolism"},{"issue":"3","key":"247_CR195","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1124\/jpet.119.261792","volume":"371","author":"C Tian","year":"2019","unstructured":"Tian C, Gao L, Zhang A, Hackfort BT, Zucker IH. Therapeutic effects of NRF2 activation by bardoxolone methyl in chronic heart failure. J Pharmacol Exp Ther. 2019 Dec;371(3):642\u201351.","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"247_CR196","doi-asserted-by":"publisher","first-page":"e0263080","DOI":"10.1371\/journal.pone.0263080","volume":"17","author":"K Ogiso","year":"2022","unstructured":"Ogiso K, Shayo SC, Kawade S, Hashiguchi H, Deguchi T, Nishio Y. Repeated glucose spikes and insulin resistance synergistically deteriorate endothelial function and bardoxolone methyl ameliorates endothelial dysfunction. Bader M, editor. PLoS One. 2022 Jan 24;17(1):e0263080.","journal-title":"PLoS One"},{"key":"247_CR197","doi-asserted-by":"crossref","unstructured":"Houshialsadat Z, Mirmiran P, Zare-Javid A, Bahadoran Z, Houghton C. Beneficial effects of sulforaphane-yielding broccoli sprout on cardiometabolic health: a systematic review and meta-analysis. Jundishapur J Nat Pharm Prod [Internet]. 2022 Oct 18 [cited 2025 Aug 15];17(4). Available from: https:\/\/brieflands.com\/articles\/jjnpp-129402.html.","DOI":"10.5812\/jjnpp-129402"},{"issue":"4","key":"247_CR198","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1002\/cbf.3795","volume":"41","author":"MM Atef","year":"2023","unstructured":"Atef MM, Hafez YM, El-Deeb OS, Basha EH, Ismail R, Alshenawy H, et al. The cardioprotective effect of human glucagon-like peptide-1 receptor agonist (semaglutide) on cisplatin-induced cardiotoxicity in rats: targeting mitochondrial functions, dynamics, biogenesis, and redox status pathways. Cell Biochem Function. 2023 Jun;41(4):450\u201360.","journal-title":"Cell Biochem And Function"},{"issue":"2","key":"247_CR199","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1530\/JOE-17-0457","volume":"236","author":"P Tanajak","year":"2018","unstructured":"Tanajak P, Sa-Nguanmoo P, Sivasinprasasn S, Thummasorn S, Siri-Angkul N, Chattipakorn SC, et al. Cardioprotection of dapagliflozin and vildagliptin in rats with cardiac ischemia-reperfusion injury. J Endocrinol. 2018 Feb;236(2):69\u201384.","journal-title":"J Endocrinol"},{"key":"247_CR200","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.redox.2017.12.019","volume":"15","author":"H Zhou","year":"2018","unstructured":"Zhou H, Wang S, Zhu P, Hu S, Chen Y, Ren J. Empagliflozin rescues diabetic myocardial microvascular injury via AMPK-mediated inhibition of mitochondrial fission. Redox Biol. 2018 May;15:335\u201346.","journal-title":"Redox Biol"},{"issue":"5","key":"247_CR201","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1111\/jdi.12802","volume":"9","author":"S Takagi","year":"2018","unstructured":"Takagi S, Li J, Takagaki Y, Kitada M, Nitta K, Takasu T, et al. Ipragliflozin improves mitochondrial abnormalities in renal tubules induced by a high-fat diet. J Diabetes Invest. 2018 Sep;9(5):1025\u201332.","journal-title":"J Diabetes Invest"},{"issue":"5","key":"247_CR202","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s12012-024-09852-7","volume":"24","author":"D Zhou","year":"2024","unstructured":"Zhou D, Yang Y, Chen J, Zhou J, He J, Liu D, et al. N-acetylcysteine protects against myocardial ischemia-reperfusion injury through anti-ferroptosis in type 1 diabetic mice. Cardiovasc Toxicol. 2024 May;24(5):481\u201398.","journal-title":"Cardiovasc Toxicol"},{"issue":"1","key":"247_CR203","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/1475-2840-10-43","volume":"10","author":"KR Gibson","year":"2011","unstructured":"Gibson KR, Winterburn TJ, Barrett F, Sharma S, MacRury SM, Megson IL. Therapeutic potential of N-acetylcysteine as an antiplatelet agent in patients with type-2 diabetes. Cardiovasc Diabetol. 2011 Dec;10(1):43.","journal-title":"Cardiovasc Diabetol"},{"key":"247_CR204","doi-asserted-by":"crossref","unstructured":"Samimi F, Namiranian N, Sharifi-Rigi A, Siri M, Abazari O, Dastghaib S. Coenzyme Q10: a key antioxidant in the management of diabetes-induced cardiovascular complications-an overview of mechanisms and clinical evidence. Song, X, editor. Int J Endocrinol. 2024 Mar 15;2024:1\u201313.","DOI":"10.1155\/2024\/2247748"},{"key":"247_CR205","doi-asserted-by":"publisher","first-page":"1506460","DOI":"10.3389\/fcvm.2025.1506460","volume":"12","author":"M Pang","year":"2025","unstructured":"Pang M, Wang S, Shi T, Chen J. Overview of MitoQ on prevention and management of cardiometabolic diseases: a scoping review. Front Cardiovasc Med. 2025 Mar 11;12:1506460.","journal-title":"Front Cardiovasc Med"},{"issue":"6","key":"247_CR206","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1161\/HYPERTENSIONAHA.117.10787","volume":"71","author":"MJ Rossman","year":"2018","unstructured":"Rossman MJ, Santos-Parker JR, Steward CAC, Bispham NZ, Cuevas LM, Rosenberg HL, et al. Chronic supplementation with a mitochondrial antioxidant (MitoQ) improves vascular function in healthy older adults. Hypertension. 2018 Jun;71(6):1056\u201363.","journal-title":"Hypertension"},{"key":"247_CR207","doi-asserted-by":"publisher","first-page":"112402","DOI":"10.1016\/j.exger.2024.112402","volume":"189","author":"S Nemati","year":"2024","unstructured":"Nemati S, Zavvari-Oskuye Z, Bafadam S, Mokhtari B, Badalzadeh R, Vakili A. Impact of combined alpha-lipoic acid and mitoquinone supplementation on myocardial infarction in aged rats: heart performance and molecular mechanisms. Exp Gerontolo. 2024 May;189:112402.","journal-title":"Exp Gerontolo"},{"issue":"1","key":"247_CR208","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1097\/CM9.0000000000003230","volume":"138","author":"X Chen","year":"2025","unstructured":"Chen X, Xie N, Feng L, Huang Y, Wu Y, Zhu H, et al. Oxidative stress in diabetes mellitus and its complications: from pathophysiology to therapeutic strategies. Chin Med J. 2025 Jan 5;138(1):15\u201327.","journal-title":"Chin Med J"},{"key":"247_CR209","unstructured":"U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Multi-discipline review and evaluation: NDA 209203 (duzallo, lesinurad\/allopurinol) [Internet]. Silver Spring, MD: U.S. Food and Drug Administration. 2017 [cited 2025 Aug 13] p. 141. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2017\/209203Orig1s000MultidisciplineR.pdf."},{"issue":"7","key":"247_CR210","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1093\/ajh\/hpaa052","volume":"33","author":"E Amiya","year":"2020","unstructured":"Amiya E. Nrf-2: the target of vascular dysfunction in diabetes. Am J Hypertens. 2020 Jul 18;33(7):597\u201398.","journal-title":"Am J Hypertens"},{"key":"247_CR211","doi-asserted-by":"publisher","first-page":"382","DOI":"10.3389\/fphar.2019.00382","volume":"10","author":"RM Da Costa","year":"2019","unstructured":"Da Costa RM, Rodrigues D, Pereira CA, Silva JF, Alves JV, Lobato NS, et al. NRF2 as a potential mediator of cardiovascular risk in metabolic diseases. Front Pharmacol. 2019 Apr 12;10:382.","journal-title":"Front Pharmacol"},{"key":"247_CR212","doi-asserted-by":"publisher","first-page":"106918","DOI":"10.1016\/j.phrs.2023.106918","volume":"196","author":"SXH Mthembu","year":"2023","unstructured":"Mthembu SXH, Mazibuko-Mbeje SE, Moetlediwa MT, Muvhulawa N, Silvestri S, Orlando P, et al. Sulforaphane: a nutraceutical against diabetes-related complications. Pharmacol Res. 2023 Oct;196:106918.","journal-title":"Pharmacol Res"},{"issue":"2","key":"247_CR213","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.apsb.2021.10.005","volume":"12","author":"X Wang","year":"2022","unstructured":"Wang X, Chen X, Zhou W, Men H, Bao T, Sun Y, et al. Ferroptosis is essential for diabetic cardiomyopathy and is prevented by sulforaphane via AMPK\/NRF2 pathways. Acta Pharm Sin B. 2022 Feb;12(2):708\u201322.","journal-title":"Acta Pharm Sin B"},{"issue":"7","key":"247_CR214","doi-asserted-by":"publisher","first-page":"966","DOI":"10.3390\/ph18070966","volume":"18","author":"V Schiavoni","year":"2025","unstructured":"Schiavoni V, Di Crescenzo T, Membrino V, Alia S, Fantone S, Salvolini E, et al. Bardoxolone methyl: a comprehensive review of its role as a NRF2 activator in anticancer therapeutic applications. Pharmaceuticals. 2025 Jun 27;18(7):966.","journal-title":"Pharmaceuticals"},{"issue":"6","key":"247_CR215","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/j.ekir.2020.03.030","volume":"5","author":"M Nangaku","year":"2020","unstructured":"Nangaku M, Kanda H, Takama H, Ichikawa T, Hase H, Akizawa T. Randomized clinical trial on the effect of bardoxolone methyl on GFR in diabetic kidney disease patients (TSUBAKI study). Kidney Int Rep. 2020 Jun;5(6):879\u201390.","journal-title":"Kidney Int Rep"},{"key":"247_CR216","unstructured":"UBE Corporation. Licensing agreement for novel NRF2 activator. 2025 Jul 14; Available from: https:\/\/www.ube.com\/ube\/en\/news\/2025\/0714.html."},{"issue":"8","key":"247_CR217","doi-asserted-by":"publisher","first-page":"e202503330","DOI":"10.26508\/lsa.202503330","volume":"8","author":"S Kaseda","year":"2025","unstructured":"Kaseda S, Horizono J, Sannomiya Y, Kuwazuru J, Suico MA, Sato R, et al. Efficacy of NRF2 activation in a proteinuric alport syndrome mouse model. Life Sci Alliance. 2025 Aug;8(8):e202503330.","journal-title":"Life Sci Alliance"},{"issue":"12","key":"247_CR218","doi-asserted-by":"publisher","first-page":"103517","DOI":"10.1016\/j.isci.2021.103517","volume":"24","author":"A Ishikita","year":"2021","unstructured":"Ishikita A, Matsushima S, Ikeda S, Okabe K, Nishimura R, Tadokoro T, et al. GFAT2 mediates cardiac hypertrophy through HBP-O-GlcNAcylation-Akt pathway. iScience. 2021 Dec;24(12):103517.","journal-title":"iScience"},{"issue":"6","key":"247_CR219","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1042\/BCJ20160980","volume":"474","author":"D Zibrova","year":"2017","unstructured":"Zibrova D, Vandermoere F, G\u00f6ransson O, Peggie M, Mari\u00f1o KV, Knierim A, et al. GFAT1 phosphorylation by AMPK promotes VEGF-induced angiogenesis. The Biochemical J. 2017 Mar 15;474(6):983\u20131001.","journal-title":"The Biochemical J"},{"issue":"1","key":"247_CR220","first-page":"1","volume":"38","author":"I Obilineni","year":"2025","unstructured":"Obilineni I, Ramachandran V, Magesh H. Targeting GFAT for diabetes management: a therapeutic approach to alleviate hexosamine pathway-induced complications. Marmara Med J. 2025 Jan;38(1):1\u20138.","journal-title":"Marmara Med J"},{"issue":"1","key":"247_CR221","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s40203-021-00084-z","volume":"9","author":"VO Ukwenya","year":"2021","unstructured":"Ukwenya VO, Adelakun SA, Elekofehinti OO. Exploring the antidiabetic potential of compounds isolated from Anacardium occidentale using computational aproach: ligand-based virtual screening. Silico Pharmacol. 2021 Apr 3;9(1):25.","journal-title":"Silico Pharmacol"},{"issue":"3","key":"247_CR222","doi-asserted-by":"publisher","first-page":"H815","DOI":"10.1152\/ajpheart.00756.2008","volume":"296","author":"AG Rajapakse","year":"2009","unstructured":"Rajapakse AG, Ming XF, Carvas JM, Yang Z. The hexosamine biosynthesis inhibitor azaserine prevents endothelial inflammation and dysfunction under hyperglycemic condition through antioxidant effects. Am J Physiol Heart Circ Physiol. 2009 Mar;296(3):H815\u201322.","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"1","key":"247_CR223","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/s41420-021-00656-0","volume":"7","author":"W Li","year":"2021","unstructured":"Li W, Li W, Wang Y, Leng Y, Xia Z. Inhibition of DNMT-1 alleviates ferroptosis through NCOA4 mediated ferritinophagy during diabetes myocardial ischemia\/reperfusion injury. Cell Death Discov. 2021 Sep 29;7(1):267.","journal-title":"Cell Death Discov"},{"key":"247_CR224","doi-asserted-by":"crossref","unstructured":"Mohammed SA, Albiero M, Ambrosini S, Gorica E, Karsai G, Caravaggi CM, et al. The BET protein inhibitor apabetalone rescues diabetes-induced impairment of angiogenic response by epigenetic regulation of thrombospondin-1. Antioxid Redox Signaling. 2022 Apr;1(36(10\u201312):667\u201384.","DOI":"10.1089\/ars.2021.0127"},{"issue":"1","key":"247_CR225","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s12933-020-01199-x","volume":"20","author":"T BETonMace Investigators","year":"2021","unstructured":"The BETonMACE Investigators, Nicholls SJ, Schwartz GG, Buhr KA, Ginsberg HN, Johansson JO, et al. Apabetalone and hospitalization for heart failure in patients following an acute coronary syndrome: a prespecified analysis of the BETonMACE study. Cardiovasc Diabetol. 2021 Dec;20(1):13.","journal-title":"Cardiovasc Diabetol"},{"issue":"18","key":"247_CR226","doi-asserted-by":"publisher","first-page":"3482","DOI":"10.1093\/cvr\/cvac142","volume":"118","author":"TA McKinsey","year":"2023","unstructured":"McKinsey TA, Foo R, Anene-Nzelu CG, Travers JG, Vagnozzi RJ, Weber N, et al. Emerging epigenetic therapies of cardiac fibrosis and remodelling in heart failure: from basic mechanisms to early clinical development. Cardiovasc Res. 2023 Feb 3;118(18):3482\u201398.","journal-title":"Cardiovasc Res"},{"key":"247_CR227","doi-asserted-by":"publisher","first-page":"870999","DOI":"10.3389\/fcvm.2022.870999","volume":"9","author":"B Zhang","year":"2022","unstructured":"Zhang B, Zhang J, Liu G, Guo X, Liu X, Chen J. KDM3A inhibition ameliorates hyperglycemia-mediated myocardial injury by epigenetic modulation of nuclear factor kappa-B\/P65. Front Cardiovasc Med. 2022 Apr 29;9:870999.","journal-title":"Front. Cardiovasc. Med"},{"issue":"1","key":"247_CR228","doi-asserted-by":"publisher","first-page":"5521","DOI":"10.1038\/s41598-024-55923-8","volume":"14","author":"N Chang","year":"2024","unstructured":"Chang N, Li J, Lin S, Zhang J, Zeng W, Ma G, et al. Emerging roles of SIRT1 activator, SRT2104, in disease treatment. Sci Rep. 2024 Mar 6;14(1):5521.","journal-title":"Sci Rep"},{"issue":"1","key":"247_CR229","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1146\/annurev.med.46.1.223","volume":"46","author":"MDM Brownlee","year":"1995","unstructured":"Brownlee MDM. Advanced protein glycosylation in diabetes and aging. Annu Rev Med. 1995 Feb;46(1):223\u201334.","journal-title":"Annu. Rev. Med"},{"issue":"6779","key":"247_CR230","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/35008121","volume":"404","author":"T Nishikawa","year":"2000","unstructured":"Nishikawa T, Edelstein D, Du XL, Ichi YS, Matsumura T, Kaneda Y, et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature. 2000 Apr 1;404(6779):787\u201390.","journal-title":"Nature"},{"issue":"6","key":"247_CR231","doi-asserted-by":"publisher","first-page":"36","DOI":"10.69750\/dmls.01.06.058","volume":"1","author":"A Javed","year":"2024","unstructured":"Javed A, Tariq M, Hussain G, Ali ST, Fatima A, Batool A, et al. Advances in personalized medicine and genomics for diabetes type-2 management towards precision health: genomic insights into type-2 diabetes. Dev Med Life Sci. 2024 Sep 30;1(6):36\u201344.","journal-title":"Dev Med Life Sci"},{"issue":"7","key":"247_CR232","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.3390\/biomedicines13071723","volume":"13","author":"A Mitsis","year":"2025","unstructured":"Mitsis A, Khattab E, Kyriakou M, Sokratous S, Sakellaropoulos SG, Tzikas S, et al. Genomic and precision medicine approaches in atherosclerotic cardiovascular disease: from risk prediction to therapy-a review. Biomedicines. 2025 Jul 14;13(7):1723.","journal-title":"Biomedicines"}],"container-title":["Cardiovascular Diabetology \u2013 Endocrinology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40842-025-00247-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40842-025-00247-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40842-025-00247-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T23:03:08Z","timestamp":1765494188000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40842-025-00247-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,12]]},"references-count":232,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["247"],"URL":"https:\/\/doi.org\/10.1186\/s40842-025-00247-3","relation":{},"ISSN":["3059-4057"],"issn-type":[{"value":"3059-4057","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,12]]},"assertion":[{"value":"6 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The author declares no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"39"}}